Aletho News

ΑΛΗΘΩΣ

They Attempt to Justify Approval for Use in Infants and Toddlers

They want the COVID-19 vaccine approval for children so bad, Peter Marks himself and his cronies published the very study he has to use to evaluate for approval.

By James Lyons-Weiler | Popular Rationalism | June 11, 2022

As promised, the FDA has ginned up a report that ostensibly will be used to try to justify “approval” (whatever they mean by that now) of COVID-19 vaccines for infants and toddlers (children < 5 years old). Here’s the report for your reference.

This report comes after a torrent of massive reports from Moderna and Pfizer that claim to review studies of the safety and efficacy of COVID-19 vaccines in children. It is not hard to see what shenanigans the FDA has been up to to try to bolster a vaccine that fewer and fewer adults want. It’s more of the same: exaggerate the apparent risk of the virus and minimizing the perception of risk. In other words, lies.

  1. There is no evidence of clinical urgency. Infants and toddlers (and children in general) do not get COVID-19; they do not (yet) die from COVID-19. All that can change when antibody dependent enhancement kicks in for the vaccinated. FDA’s own reports cites 1,086 deaths “from COVID-19” and 10,700,000 “cases” of COVID-19 in children aged 0-17. There have been 832 days since April 1, 2020 when diagnoses started for COVID-19. For the entire population of children in the US (73,000,000), the risk of COVID-19 infection since the onset of COVID is 10,700,000/73,000,000 = 0.14657. The risk of a child dying if they have a diagnosis is 1,086/10,700,00 or 1086/10700000 = 0.00010149532. The risk of any child dying of COVID-19 over this time period is 1,086/73000000 = 0.00001487671. The per-day risk is on the order of 1.78806611e-8 (0.000000001788). There is no real unmet clinical need and the FDA needs to go back to college to understand how to use RT-PCR correctly. Children do not get COVID-19, and they do not die.
  2. Inconsistent use of the idea “vaccinated”. This has been the pattern from the very first study. FDA, CDC, Moderna, Pfizer, and others pull out whatever definition of “vaccinated” they want. Examples: “Vaccinated” is defined in the original trials as people who received both doses and who did not develop COVID-19 before two weeks passed after the second exposure to the vaccine. In fact, that means that people who developed COVID-19 due to disease enhancement were dropped from the study calculations. First, this is the first time people were dropped from a vaccine trial for getting infected with the pathogen targeted by the vaccine up to 13 or 14 days after being vaccinated. Second, it’s actually five entire weeks – one month and one week – 44 days – after the first exposure. ALL of the vaccine efficacy being cited by FDA is suspect. Moderna’s and Pfizer’s vaccines never achieved >90% true vaccine efficacy; the best estimate is more like 75%.
  3. Inconsistent use of the idea “vaccine efficacy”. Over the time period since the first COVID-19 vaccine trials, various definitions of “vaccine efficacy” have been used. Decreased transmission. Reduction in infection rates. Reduced hospitalization. Presence of neutralizing antibodies. Presence of antibodies. All are used and cited in FDA’s report whenever convenient, all in an ad-hoc manner. It’s more than irritating. It’s moving the goal post and represents reckless (and ineffective) attempts to manipulate public perception. This practice continues in the reports and studies that are cited by FDA. I do not trust the efficacy data FDA cites in their report (why would we given Point 1?).Further evidence of the futility of the evidence used to claim efficacy comes from Moderna’s Sponsor Briefing report to the FDA:“3.3 Regulatory Considerations for Clinical Development of COVID-19 Vaccines in Children

    Effectiveness

    Regulatory precedent with other preventive vaccines provides a basis for inference of vaccine effectiveness in pediatric populations based on immunobridging to a young adult population in which clinical disease endpoint vaccine efficacy has been demonstrated for the same prototype vaccine. The immune marker(s) used for immunobridging do not need to be scientifically established to predict protection but should be clinically relevant to the disease. Based on available data in humans and animal models, FDA considers neutralizing antibody titers (a functional measure of the vaccine immune response against SARS-CoV-2) to be clinically relevant for immunobridging to infer effectiveness of COVID-19 vaccines in pediatric age groups. Because no specific neutralizing antibody titer has been established to predict protection against COVID-19, two immunogenicity endpoints (GMT and SRR) are considered appropriate for comparing the range of neutralizing antibody responses elicited by the vaccine in pediatric versus young adult populations.

    Also embedded in this piece of work is the fact that FDA does not need evidence of long-term immunity; they are settling for something called “immunobridging” – guessing at the efficacy of a vaccine in one clinical population from measurements made from other clinical populaton.

    They also are making people dependent on vaccines… expecting patients to have antibodies from one vaccine to the next. This makes no sense immunologically. We don’t need continuously high antibody levels against any pathogen. We have memory B-cells and T-cells. In accepting this paradigm, FDA is completely off its rocker and will cause immune exhaustion with constant vaccinations every 3-4 months.

  4. Incomplete consideration of the scientific data (Barnstable County, Israel, Ontario). We know that months after vaccination, those who are vaccinated are at higher risk of infection and now of hospitalizations. Data actually show negative vaccine efficacy in children (per Jeremy Hammond). See: “Evidence for Negative COVID-19 Vaccine Effectiveness in Children”. From that article:“vaccine effectiveness (VE) in children becomes(sic) negative within several months since receipt of the second dose.Researchers from the New York State Department of Health published a study on the preprint server medRxiv on February 28 noting that the evidence for vaccine effectiveness in children, particularly those aged five to eleven, was “limited”. So, they aimed to provide data to inform policymaking.“During Omicraon variant predominance,” the authors concluded, “VE against infection declined rapidly” for young children in the state of New York, “with low protection by one month following full-vaccination.”Comparing COVID-19 cases during January between unvaccinated and vaccinated children, they estimated initial vaccine effectiveness for children aged twelve to seventeen to be 76 percent, but this dropped to below 50 percent after just five weeks since receipt of the second dose.Moreover, for young children (aged five to eleven), they observed a drop from 65 percent to just 12 percent after only one month.Thereafter, their estimate indicated significantly negative effectiveness for this age group, as shown in Figure 2 of their paper: by 35 to 41 days, VE reached negative 10 percent, and by 42 to 48 days, it reached negative 41 percent.

    Jeremy goes on to report (correctly) that the authors of the article misinterpreted their own data. History will remember Jeremy as a reporter with great integrity.

  5. Moderna and Pfizer reports fail to study long-term risks. Like I said, more of the same shenanigans. In this report, for example, Moderna offers data on myocarditis only up to Day 28 after the vaccine. Why Day 28? Why not “since the vaccine has been administered” to more accurately reflect the real-world clinical situation? They also state that myocarditis in a large concern in people infected with SARS-CoV-2 – but the comparison is to the uninfected, not the vaccinated, and we know that the spike protein is the cause (syncytia among heart muscles caused by the spike protein). The spike protein, of course, is the basis of their mRNA vaccines.
  6. Incestuous COIs/Unjustified Influence by Regulators. Peter Marks is charged with setting the decisions at FDA whether to consider vaccines for specific populations. Why the hell is he involved in a study conducted to bolster the vaccines he is going to have to decide upon? See “Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16–29 years”. That “study” is also guilty of all of the same loose logic as above; it is noteworthy that the study assumes as “worst case scenario” of zero deaths from myocarditis following COVID-19 vaccination (Credit: Toby McDonald, who wrote this to me:“I’m reading the Moderna “Sponsor Briefing Document” and they built their benefit-risk assessment off of Funk et al. (2022). So I looked up Funk and it’s a recent paper by six staffers at the FDA including Peter Marks, Richard Forshee, and Hong Yang (who wrote the dreadful benefit-risk assessment for kids 5 to 11 back in October). Quite literally in their “worst-case scenario” they predict 0 deaths from myocarditis in the vaccine group. It’s a stunning work of fiction.”
  7. I’m on an email thread with Steve Kirsch (he considers me part of his “debate team”. Last week, Steve challenged Peter Marks to a debate:“Hi Peter,You are right about the vaccine uptake problem. According to independent survey we just commissioned, only 33% of Americans opted to go further than the first 2 doses.You were quoted in that CNN article:“We do have a problem with vaccine uptake that is very serious in the United States and anything we can do to get people more comfortable to be able to accept these potentially life-saving medical products is something that we feel we are compelled to do,” said Dr. Peter Marks, director of the Center for Biologics Evaluation and Research.Isn’t it time for you to end the misinformation problem by debating us in a public forum?My colleagues and I look forward to hearing from you.

    The only way to end the misinformation is to debate the top misinformation spreaders. You will never win by trying to censor us.

    We would be HAPPY to debate to you to end the misinformation problem. As you can see from this slide deck, all the evidence we’ve been able to find shows there was clinical trial fraud and that the vaccines are very dangerous. We would love to know how we got it wrong

    I look forward to hearing from you.

    -steve

    To my knowledge, Marks has not replied. I replied to Steve and the entire email thread, including Marks, though:

    “Steve,

    History is going to remember one person on this email thread in a manner in which I would not ever care to be seen associating with.

    I would therefore decline to participate in such a debate.

    Sincerely,

    James Lyons-Weiler, PhD

I could continue and debate dozens more points in the report dump by the FDA. I don’t have to. Marks himself provides evidence of being way off-target immunologically and lying about the “need” for COVID-19 vaccines for children.

Here’s an old video of Prevaricating Peter lying about the need for “high antibody titres” for immunity, and that children’s immune response is “not enough for some of these variants” (no data on that, just words):

The comments in that video have not aged well. Call your Senator and Congressional Reps and demand that Peter Marks resign. Email them this article. Marks and the FDA are NOT basing their considerations on independent fact, science and logic. He and his cronies are either incompetent or working for the industry. Either way, he and his cronies have to go.

June 14, 2022 Posted by | Deception, Science and Pseudo-Science, War Crimes | , , , , , | Leave a comment

Parsing the “data” from Moderna’s selective leaks to the press about its failed clinical trial in kids under 6

The shot made no difference against Covid but it does cause myocarditis and came with a 15% to 17% adverse event rate. Meanwhile the CDC admits that 74.2% of kids already have natural immunity.

By Toby Rogers | April 30, 2022

On Friday, the NY Times and other stenographers for the cartel breathlessly announced that Moderna has asked the FDA to authorize its junk science mRNA shot in kids under 6. Oh, so that means Moderna submitted an application to the FDA? Well, not exactly. From the article:

“A top official at the company said it would finish submitting data to regulators by May 9.”

Wait, so Moderna is “asking” the FDA to authorize its product but Moderna will not even finish its application for another 10 days!? That’s weird. It’s like a kid asking his teacher for a A+ while his homework assignment is half-finished.

So already we’re seeing serious red flags and we’re not even out of the first paragraph.

Of course it gets worse.

To be clear, there is no data because Moderna has not even finished its application. But Moderna and the White House have been selectively leaking numbers to the press that dutifully prints them without question — and those numbers tell us that Moderna’s clinical trial was a disaster.

I need to provide some background and context and then I’ll get into the particular details about this failed clinical trial in kids.

Moderna applied for Emergency Use Authorization to administer its mRNA shot to adolescents 12 to 17 years old back on June 10, of 2021. But the application has been held up ever since. Why? Myocarditis. From the Wall Street Journal :

The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s mRNA Covid-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare inflammatory heart condition, according to people familiar with the matter.

Moderna has at least two big problems in giving this shot to teenagers:

1) The dose they are giving to teenagers is the same dose as that given to adults — 100 mcg of mRNA — which is four times the amount in the Pfizer shot given to adults (25 mcg). So the Moderna shot is great at generating antibodies that target the spike protein of the original Wuhan lab leak strain. But some of that mRNA can migrate to the heart and generate myocarditis as well. Remember, Pharma’s capture of the FDA is so extreme, they should just be able to write “Iz Gud!” on a paper napkin and the FDA will approve it — as they did with Pfizer’s application to inject kids 5 to 11 — in spite of ZERO evidence supporting this use. So if the FDA has held up Moderna’s application in teens for nearly a year, the myocarditis signal must be truly terrifying.

2) Nordic countries are slightly less corrupt than the United States. Finland, Sweden, Denmark, and Norway have all suspended the use of the Moderna mRNA shot in teenagers because its leads to myocarditis. (Finland and Sweden even suspended its use in men under 30 years old.) Even the criminally corrupt European Medicines Agency acknowledged that both Pfizer and Moderna mRNA shots lead to myo- and pericarditis and added a warning to the product insert.

Okay what do we know about Moderna’s clinical trial in kids under 6?

Back on March 23, Moderna put out a press release claiming that:

vaccine efficacy in children 6 months to 2 years was 43.7% and vaccine efficacy was 37.5% in the 2 to under 6 years age group.

The NY Times of course printed that like it was a clay tablet handed directly from God to Moses just as they printed the “90% to 100% effective(TM)” lie in connection with the clinical trial in adults. By now everyone knows that the actual vaccine effectiveness is zero or even negative after 6 months.

Sane people pointed out that vaccine efficacy of 43% and 37% are BELOW the 50% threshold required for FDA authorization. It’s not clear why the geniuses at Moderna did not realize this — perhaps they just wanted to rub everyone’s noses in the sheer criminality of their enterprise?

But somewhere between March 23 and last Friday, Moderna staff got the message so they did what they always do, they just manipulated the data. From the NY Times :

Moderna said Thursday the vaccine appeared to be 51 percent effective against symptomatic infection among those younger than 2, and 37 percent effective among those 2 to 5.

Okay first off, lol that they still cannot get the number above 50% in kids 2 to 5 even when they are just straight up lying about the numbers. But how did they convert 43% to the magical 51% in kids 0 to 2? They simply deleted data that they did not like:

Those results were slightly better than the ones Moderna previously released for children under 2. The company said that was because the second time, the firm excluded infections that had not been confirmed with a P.C.R. test analyzed in a laboratory.

Let’s be clear — this is Moderna’s clinical trial. They control the whole process. If you’re a study participant who is having a heart attack in the middle of the night and call 911 and go to the hospital — they kick you out of the clinical trial for not seeing their doctors and following their protocol. So Moderna is the one who makes the decision as to whether to use “a P.C.R. test analyzed by a laboratory.” To now exclude (without any valid justification) infections that made their clinical trial look bad is gross scientific misconduct. The Moderna application, when/if it is submitted 10 days from now, should be rejected immediately because of this misconduct.

While the clinical trials in kids were failing, Pfizer and Moderna were running a half-hearted campaign to pressure the FDA to approve these shots in kids under 5 — in spite of zero data showing benefit and considerable evidence showing harms. The attempts were pathetic and included hashtags on social media like #immunizeunder5 that were likely only used by people taking money from these monsters. But of course the stenographers eagerly reported on this milquetoast effort and one of the talking points is, ‘well, okay, the shots do not meet the required 50% FDA threshold but some protection is better than none(TM) so please authorize my right to genocide my kids.’

Well, it turns out, these shots do NOT even offer “some protection”:

Moderna’s clinical trial data showed that the antibody response of the youngest children compared favorably with that of adults ages 18 to 25, meeting the trial’s primary criterion for success. Although the trial was not big enough to measure vaccine effectiveness…

What!? “The trial was not big enough to measure vaccine effectiveness.” Isn’t that the whole point of a clinical trial!? So Moderna (and the NY Times ) are saying that the clinical trial made ZERO difference on Covid-related health outcomes including infection, hospitalization, ICU visits, or deaths, because the SARS-CoV-2 virus is not a threat to healthy children in this age group — which we have been pointing out for months.

So how does Moderna try to finesse it? They look at antibodies in the blood, not health outcomes in the real world. They call it “immunobridging”. As I explained at length back in October, this is NOT a scientifically valid way to use immunobridging (claiming likely future health outcomes from antibodies alone when the trial showed no such thing). Immunobriding is only valid if one has clinically validated correlates of protection and conditions prevent one from conducting a proper RCT (neither of which apply in this case).

Even the hand-picked yes-men and women on the CDC’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) acknowledged at their last meeting that they do NOT have “correlates of protection” that would enable them to estimate health outcomes from antibody measures. Eric Rubin (Editor-in-Chief of the NEJM ) even stated, “We know what kind of antibody response can be generated, we just don’t know if it works.”

So Moderna is asking the FDA to authorize its mRNA shot in kids under 6 based on antibodies alone even though every member of the FDA’s VRBPAC acknowledges that antibodies tell you absolutely nothing about likely health outcomes.

(In fact, new evidence suggests that mRNA shots suppress the body’s innate ability to generate anti-N antibodies.)

What about side effects?

Side effects were at a similar level as those from previously approved pediatric vaccines, with fevers in 15 percent to 17 percent of the children, Moderna said.

Any shot with an adverse event rate over 1% should not be authorized. To authorize a shot with a 15 to 17% adverse event would be batsh*t insane.

Furthermore, we know that Moderna and Pfizer make cases of disability and death in their clinical trials disappear — so the actual adverse event rate is surely even higher than 15% to 17%.

Making this nightmare complete, the CDC acknowledged on April 26, 2022, that 74.2% of children ages 0 to 11 are already naturally immune to Covid-19 because of prior exposure. The 74.2% number came from February, so given the rate of increase at the time, by now nearly 100% of children ages 0 to 11 likely already have natural immunity which is superior to artificial vaccine immunity. There is no emergency in this population that would justify an emergency use authorization of this useless toxic product.

So to recap this painful saga:
• Moderna shots cause myocarditis and pericarditis which is why Moderna has not been able to get authorization to inject mRNA into teenagers.
• Moderna shots make no difference in connection with Covid-19 in this age group.
• Moderna shots come with at least a 15% to 17% adverse event rate.
• Nearly all children in this age group are already naturally immune so there is no emergency that would justify an emergency use authorization.

This is not hard to figure out. In a sane world this application would be dead on arrival, whenever Moderna gets around to actually turning in its application. Any reporter worth his/her salt should be ridiculing Moderna’s weird mix of hubris, incompetence, bad “data”, and malevolence. But our country, its “public health” agencies, and the mainstream media are run by Insane Nazi Clowns. I imagine many bougiecrats will drown in their own tears if they are not allowed to genocide their own kids with this shot (and then they’ll celebrate their sacrifice and take selfies with their kids in the ICU when the myocarditis kicks in, proclaiming #getvaccinated). Of course bougiecrats can already get this shot for their kid off label, so my hunch is that it’s really your kids who they want to genocide.

In future articles I’ll have additional thoughts about how we push back. In the meantime, this continues to be our best play and I encourage all of us to just get into the habit of contacting 25 people at the FDA every day to tell them to REJECT both the Moderna and Pfizer applications to inject mRNA into little kids.

May 1, 2022 Posted by | Corruption, Deception, Fake News, Mainstream Media, Warmongering, Science and Pseudo-Science | , , , | Leave a comment

Australian Senators raise serious Vaccine Issues in Parliament

The Naked Emperor’s Newsletter | March 31, 2022

Two Australian Senators raised some serious vaccine issues during a recent debate in their parliament. As has been the case with questions raised by other parliamentarians from around the world, these speeches were made to an empty room. Fortunately, they are recorded for the world to listen too.

The first speech is by Malcolm Roberts, Senator for Queensland. He raised the issue of documented evidence and victim testimony of vaccine injuries which are hidden behind anonymous government data. The Senator says that the very least we can do for the victims is to say their names and he precedes to recall accounts of various individuals who have died after being vaccinated.

Senator Roberts says the Australian regulators have been bullying medical practitioners not to report or talk about vaccine harms. Furthermore, he claims 98% of the 800 vaccine deaths, reported by physicians, have been erased without autopsy or consideration of medical data.

He says data recently revealed in US court papers shows vaccine harm was apparent in the Pfizer clinical trials. This information should have resulted in the refusal of the application for provisional use. No data was provided on individuals in the trials and no independent analysis of the fundamental issues surrounding novel mRNA vaccines was conducted in Australia. Instead, the Secretary just took Pfizer, AstraZeneca and Moderna’s word for it.

The Senator goes on to list the fines that these same pharmaceutical companies have been issued with (for criminal behaviour) over the years. AstraZeneca had a US $355 million fine for fraud and US $550 million fine for making unfounded efficacy claims. Pfizer had a US $430 million fine for unfounded claims about efficacy and a US $2.3 billion fine for unfounded claims about efficacy and for paying kickbacks.

Indemnities have been made against any damage caused by the vaccines which he calls deceit and criminal incompetence. Some of the Australian political parties have accepted $1 million each from the pharmaceutical companies in this election cycle alone. Billions more are being set aside in the Australian budget to continue the pharmaceutical companies’ COVID-19 gravy train.

Senator Roberts says mention should be made to the decision to ban safe, fully approved and widely accepted alternatives to COVID-19 vaccines, including hydroxychloroquine, Ivermectin, vitamins, minerals, natural antivirals, healthy eating and lifestyles. This ban was taken to ensure the fastest and widest-possible adoption of the vaccines and the vaccines approval was funded by the same pharmaceutical companies that produce them.

He thinks the Australian Bureau of Statistics is culpable in this scandal and cover-up. It’s annual budget is $400 million but the most recent mortality data is from November 2021. The most recent breakdown of mortality by cause and age is from 2020 as is the most recent data on live births. Birth data used to be available six weeks after so he asks are they hiding miscarriages?

The Senator says peer reviewed and soon to be published data is to be released from outside the government which must require the secretary to cancel the provisional approval of the vaccines.

He recaps the extent to which we have been misled:

  1. Freedom of information documents show there has been a failure to assess the reproductive toxicology of the vaccines;
  2. Documents indicate a failure to assess the impact of micro RNA sequences and related molecular genetic issues on the human body;
  3. Peer-reviewed and published in-vitro research shows gene based vaccine generated spike proteins can migrate into human cell nuclei to disrupt DNA repair mechanisms;
  4. Vaccine derived RNA can be reverse transcribed leading to possible integration into the human genome, which is denied based on what the pharmaceutical companies say.
  5. Internal Pfizer data indicate they accepted 1,272 different adverse vaccine events, including paralysis and death. German and US insurance actuarial data suggests the Australian database of adverse events notifications is under reporting by nine fold. Documents show there are two databases, an official one and one for the public meaning vaccine injury is likely to be significantly higher than reported.

He reports on German pathologists describing pathological aggregates of spike proteins and lymphocyte infiltrations in inflamed organs in autopsies related to deaths post vaccination. Whistle-blowers to the British Medical Journal provide reports on inadequacies, irregularities and possible fraudulent practises in the Pfizer vaccine trials.

Too frequent vaccines for respiratory viruses runs the risk of desensitising the immune response to the virus and lead to hypo immunity, a worse illness than without the immunisation. He says repeated vaccination is doing more harm than good.

The Senator concluded by asking a question to all those who have gone along with the deceit, “how the hell do you expect to get away with it? We’re not going to let you get away with it, we won’t let you get away with it. We’re coming for you. We have the stamina to hound you down and we damn well will.”

The next speech was by Senator Gerard Rennick, another representative from Queensland.

He says, to date, government figures show there have been over 116,000 reported, suspected adverse events to the vaccines in Australia. This is more than all other drugs put together since 1971 and the number is still climbing. Is it any wonder the Australian health system is struggling?

Most of these cases are prepared by medical professionals and almost every one has ticked the box indicating that they suspect the injury was caused by the vaccine. Anyone who has failed to speak up is destroying the lives of so many Australian people.

March 31, 2022 Posted by | Science and Pseudo-Science, Timeless or most popular, Video, War Crimes | , , , , | 4 Comments

Moderna Patented Key COVID Spike Protein Sequence in 2016

By Dr. Joseph Mercola | March 7, 2022

The facts surrounding SARS-CoV-2’s origin just keep getting stranger and more disturbing as time goes on. From the start, most of the evidence seemed to point to the virus being a lab creation that somehow escaped the confines of the laboratory. We really don’t have much of anything to suggest otherwise.

Now, a study1,2 published February 21, 2022, in Frontiers in Virology claims to have discovered that a sequence of the virus’ spike protein is a 100% match to a modified messenger RNA (mmRNA) sequence patented3 by Moderna — in 2016.

Some believe this is a smoking gun, proving gain of function research is at the heart of this mystery. Of course, more research is needed to verify the findings, but if proven correct, it could be rather incriminating.

What Did Moderna Patent?

The genetic sequence patented4 by Moderna — and now found to be part of the SARS-CoV-2’s furin cleavage site in the spike protein that gives the virus access into human cells — is a 19-nucleotide sequence of a human gene called MSH3, which is a DNA repair gene.5

Nucleotides code for specific amino acids. The MSH3 gene works with the part of your immune system responsible for combating cancer by repairing damaged cells. This pathway has been identified as a potential target for new cancer treatments.

As noted in the patent application, the gene sequence has been modified “for the production of oncology-related proteins and peptides,” ostensibly for use in cancer research. The first name listed on the patent is Stéphane Bancel, a Frenchman who has been Moderna’s chief executive officer since 2011.

What’s so curious here is that the scientists of the Frontiers in Virology paper searched all viral and bacterial databases looking for matches to the furin cleavage site patented by Moderna, and SARS-CoV-2 is the only pathogen that has this sequence. It’s an absolute match — 100% identical.

What are the chances of a naturally-occurring virus having a rarely encountered furin cleavage site that is genetically identical to an engineered and patented one? As noted by the authors:6

“The absence of CTCCTCGGCGGGCACGTAG from any eukaryotic or viral genome in the BLAST database makes recombination in an intermediate host an unlikely explanation for its presence in SARS-CoV-2.”

In other words, the sequence being a natural zoonosis is extremely unlikely. According to the researchers, the chance that SARS-CoV-2 would have randomly acquired this furin cleavage site through natural evolution is 1 in 3 trillion.7 They also noted that “Recombination in an intermediate host is an unlikely explanation.” What’s more, it’s known that inserting a furin cleavage site on the spike protein of a virus will make it more infectious.

Moderna CEO Suggests Lab Leak Responsible for COVID-19

One hypothesis raised in the paper is that the matching code might have been introduced into the SARS-CoV-2 genome through infected human cells that express the MSH3 gene. The question, then, is how and when did that happen?

Interestingly, in a February 24, 2022, interview, Fox Business host Maria Bartiromo questioned Bancel about the finding. He responded saying their scientists are looking into the claim, adding:

“That it came from a lab is possible. Humans make mistakes. It’s possible that the Wuhan lab in China was working on virus enhancement or gene modification and then there was an accident where somebody was infected in the lab, which affected family and friends. It is possible. On the claim you just mentioned, scientists will look to know if it’s real or not.”

Why This Code?

Now, if SARS-CoV-2 was man-made, why would they use this particular code? As noted in the Frontiers of Virology paper, the MSH3 sequence in question has been shown to cause mismatch repair in DNA, and faulty repair of genetic damage can lead to a number of diseases, including cancer. But overexpression of MSH3 also plays a role in virology:

“Overexpression of MSH3 is known to interfere with mismatch repair … which holds virologic importance. Induction of DNA mismatch repair deficiency results in permissiveness of influenza A virus (IAV) infection of human respiratory cells and increased pathogenicity. Mismatch repair deficiency may extend shedding of SARS-CoV-2 …

A human-codon-optimized mRNA encoding a protein 100% homologous to human MSH3 could, during the course of viral research, inadvertently or intentionally induce mismatch repair deficiency in a human cell line, which would increase susceptibility to SARS-like viral infection.”

It’s interesting to note that Moderna did not have a single successful mRNA product brought to market before the COVID-19 pandemic allowed them to bypass normal regulatory requirements.

Now, all of a sudden, we’re to believe they managed to throw together a safe and effective mRNA injection against SARS-CoV-2, a virus that just so happens to contain one of its own patented components. What are the odds?

Did Dr. Anthony Fauci, a leading promoter of mRNA technology as a replacement for traditional vaccines, have anything to do with Moderna’s sudden “success”? It certainly looks that way. After all, the National Institutes of Allergy and Infectious Diseases (NIAID), an arm of the National Institutes of Health (NIH), both funded and co-developed Moderna’s COVID-19 jab.

As explained by the NIH,8 the injection “combines Moderna’s mRNA delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P)9 developed by NIAID scientists.” In mid-November 2021, Moderna granted co-ownership of its COVID-19 mRNA “vaccine” patent to the NIH to resolve a dispute involving the naming of the inventors.10

Can the COVID Jab Trigger Cancer?

Incidentally, since the release of the mRNA COVID jab, some doctors have raised concerns about the possibility of the injections to trigger cancer, largely due to its detrimental impact on your immune function.

For clarity, this may have nothing to do with Moderna’s patented MSH3 sequence specifically, because the RNA code in the jab is not identical to the RNA code of the actual virus. The RNA in the jab has been genetically altered yet again to resist breakdown and ensure the creation of abundant copies of the spike protein.11

So far, the link to cancer post-jab seems to be related to the downregulation of toll-like receptor 4 (TLR4), which is involved in both infections and cancer. In an October 2021 article, Dr. Nicole Delépine, a French pediatric oncologist,12 discussed reports of exploding cancer cases post-jab:13

“Several months ago, we expressed at least “theoretical reservations” about vaccinating cancer patients or former patients who had been cured, because of the underlying mechanism of the gene injection on immunity.

Several geneticists had also expressed their concerns about the possible interference between active or dormant cancer cells and the activity of gene therapy on lymphocytes in particular. Months have passed, and the vaccine madness has amplified … [C]learly there seems to be three situations:

The appearance of a cancer rapidly after the injection (two weeks to a few months) and very progressive, in a person who was previously free of known carcinological pathologies.

The resumption of cancer in a patient who has been in complete remission for several months or years.

The rapid, even explosive, evolution of a cancer that is not yet controlled.

Beyond the testimonies that are pouring in from relatives and friends and on social networks, a Swiss newspaper has finally addressed the subject in a broader way. Here are some excerpts from their article and their references:

‘Can COVID vaccines cause cancer? In some cases, the answer seems to be yes … [It] has been shown that in up to 50% of vaccinees, COVID vaccines can induce temporary immunosuppression or immune dysregulation (lymphocytopenia) that can last for about a week or possibly longer.

Furthermore, COVID mRNA vaccines have shown to ‘reprogram’… adaptive and innate immune responses and, in particular, to downregulate the so-called TLR4 pathway, which is known to play an important role in the immune response to infections and cancer cells.

Thus, if there is already a tumor somewhere — known or unknown — or if there is a predisposition to a certain type of cancer, such a state of vaccine-induced immune suppression or immune dysregulation could potentially trigger sudden tumor growth and cancer within weeks of vaccination …’”

Dr. Ryan Cole, in August 2021, also reported14,15 seeing a significant increase in certain types of cancer, especially endometrial and uterine cancers, since the start of the mass injection campaign. Cole runs a large pathology laboratory in Idaho.

Other Key Components of SARS-CoV-2 Have Also Been Patented

Time will tell where this all leads, but clearly, SARS-CoV-2 does not appear to be the result of natural evolution. The evidence for it being man-made is simply overwhelming. So far, few in mainstream media have been willing to touch this story, for obvious reasons.

Finding a key gene sequence of the virus in a patent of one of the primary vaccine makers is inconvenient to say the least — and this is in addition to all the other patents relating to the virus.

As previously detailed16 by David Martin, Ph.D., SARS-CoV-2 appears to have been engineered in the 1990s, perfected in 1999 and patented in 2002. Evidence also shows that plans for mandatory vaccinations were hatched in 2015. That year, during an Academies of Science meeting, Dr. Peter Daszak, president of EcoHealth Alliance stated:

“… until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, we need to increase public understanding of the need for MCM’s [medical countermeasures] such as pan-influenza or pan-coronavirus vaccine.

A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of [the] process.”

According to Martin, “That’s admission of a felony, and the felony is domestic terrorism.” In a November 2021 Red Pill Expo speech,17 Martin reviewed the timeline of the COVID-19 jab, which began in 1990 with the first coronavirus vaccine patent for canines (dogs) filed by Pfizer.

That vaccine was an S-1 spike protein vaccine — just like the current Pfizer COVID shot, and according to Martin, that S-1 spike protein is a bioweapon, not a pathogen. Nine years later, in 1999, Fauci, as director of the NIAID, tasked the University of North Carolina Chapel Hill with the creation of “an infectious replication-defective coronavirus” specifically targeted for human lung epithelium.

The patent for that replication-defective coronavirus that attacks human lung cells, filed April 19, 2002, (Patent No. 7279327), details the gene sequencing of the resulting virus, and how the ACE receptor, the ACE2 binding domain and the S-1 spike protein were engineered and could be synthetically modified in the lab using readily available gene sequencing technologies.

Basically, computer code is turned into a manmade pathogen, or an intermediate pathogen. This technology was initially funded in order to harness the coronavirus as a vector for an HIV vaccine, but it clearly didn’t end there.

CDC Holds Patents on SARS Coronavirus

The U.S. Centers for Disease Control and Prevention also holds key patents, including an illegally obtained patent for the entire gene sequence for the SARS coronavirus (Patent No. 7220852), which Martin says is 99% identical to the sequence now identified as SARS-CoV-2.

That CDC patent also had several derivative patents associated with it, including U.S. patent 46592703P and U.S. patent 7776521, which cover the gene sequence of SARS coronavirus and the means for detecting it using RT PCR testing. With these two patents, the CDC has complete scientific control, as it owns the provenance of both the virus and its detection.

According to Martin, there’s also evidence of a criminal conspiracy involving the CDC and Sequoia Pharmaceuticals. April 28, 2003 — three days after the CDC filed its patent for the SARS coronavirus — Sequoia Pharmaceuticals filed a patent on an antiviral agent for the treatment and control of infectious coronavirus (Patent No. 7151163).

So, the CDC filed a patent on SARS coronavirus, and three days later there’s a treatment? This strongly suggests there was a working relationship behind the scenes. Sequoia Pharmaceuticals, founded in 2002, develops antiviral therapeutics with a special focus on drug-resistant viruses.18 Its lead investors include the Wellcome Trust.

But there’s yet another problem with Sequoia’s 2003 filing for an antiviral agent. It was actually issued and published before the CDC patent on SARS coronavirus had been granted, which didn’t happen until 2007, and the CDC had paid to keep the application private.

So, there is zero possibility for anyone but an insider to have that information. This is clear evidence of criminal conspiracy, racketeering and collusion, Martin notes. You cannot develop a treatment for something that you do not know exists.

Sanofi also owns a series of patents detailing what we’ve been told are novel features of SARS-CoV-2, namely the polybasic cleavage site, the spike protein and the ACE2 receptor binding domain. The first of those patents, U.S. Patent No. 9193780, was issued November 24, 2015.

Between 2008 and 2017, a series of patents were also filed by a long list of players, including Crucell, Rubeus Therapeutics, Children’s Medical Corporation, Ludwig-Maximilians-Universität in München, Protein Science Corporation, Dana-Farber Cancer Institute, University of Iowa, University of Hong Kong and the Chinese National Human Genome Center in Shanghai.

According to Martin, there are 73 patents, issued between 2008 and 2019, that describe the very elements that are said to be unique to SARS-CoV-2. It’s unclear whether Moderna’s 2016 patent filing is part of that list.

Sources and References

March 8, 2022 Posted by | Science and Pseudo-Science, Timeless or most popular | , , , , , , | Leave a comment

Vaccinators Won’t Stop Vaccinating

By Dr. Joseph Mercola | February 4, 2022

Many experts have sounded the alarm that the COVID-19 pandemic was all about the shot1 and a larger agenda to impose totalitarian control worldwide.2 Already, one shot has turned into two doses and a third booster. A fourth booster is also being discussed, including by Moderna CEO Stéphane Bancel, who said that the efficacy of the third shot is likely to decline over several months, necessitating another shot soon thereafter.3

“I will be surprised when we get that data in the coming weeks that it’s holding nicely over time — I would expect that it’s not going to hold great,” Bancel said in an interview with Goldman Sachs.4 Conveniently, Moderna is working on an Omicron-specific jab that they hope to release as early as March 20225 — and this is only the beginning.

Writing on Substack, contributor Eugyppius explained, “Moderna, just one of multiple pharmaceuticals eager to exploit our new vaccine mania, are expanding their manufacturing capacity to produce as many as 6 billion mRNA vaccine doses per year.”6 The information came straight from the horse’s mouth, at a virtual meeting held the first day of the World Economic Forum’s (WEF) Davos Agenda 2022, at a session titled “COVID-19: What’s Next?”7

Along with Bancel, the meeting was attended by Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI), and professor Annelies Wilder-Smith from the London School of Hygiene and Tropical Medicine, who together detailed their plans for “vaccine mania” to persist indefinitely.

Combined Shots Planned to Avoid ‘Compliance Issues’

During the discussion, Bancel states that Moderna is actively preparing for “what should the vaccine be in the fall of 2022, and what should it contain.” The company is “working with public health experts like Fauci’s team to figure this out. Because soon we’re going to have to decide what goes into the vaccine for fall of 2022,” he said.8

Fauci’s NIAID is part of the U.S. National Institutes of Health (NIH), which, some may be surprised to learn, actually owns half the patent for Moderna’s COVID-19 injection. In fact, the NIH owns thousands of pharmaceutical patents, and the U.S. Centers for Disease Control and Prevention spends $4.9 billion a year out of its $12 billion budget buying and distributing vaccines.

“Tony Fauci was able to choose, to designate, four of his high-level employees who each get individual patent shares,” according to Robert F. Kennedy Jr. in an interview with James Corbett.9 “They will collect $150,000 a year for life if the Moderna vaccine is approved, which it has been.”10

In addition to working closely with Fauci, Moderna is planning to combine multiple shots, such as a COVID-19 shot, a flu shot and a respiratory syncytial virus (RSV) shot, into one injection — coming in 2023 — to help avoid “compliance issues.” He said:11

“The other piece we’re working on is for 2023, is how do we make it possible from a societal standpoint that people want to be vaccinated?

And we’re going to do this by preparing combinations, we’re working on the flu vaccine, we’re working on an RSV vaccine, and our goal is to be able to have a single annual booster, so that we don’t have compliance issues, where people don’t want to get two to three shots a winter, but they get one dose, where they get a booster for corona, and a booster for flu and RSV, to make sure that people get their vaccine.”

When asked how soon this would occur, he continued:12,13

“So the RSV program is now in Phase 3, the flu program is in Phase 2 and soon in Phase 3, I hope as soon as second quarter of this year. So the best case scenario would be the fall of 2023, as a best case scenario, I don’t think it would [be available] in every country, but we believe it’s possible to operate in some countries next year.”

Vaccines for at Least 20 Pathogens in the Works

SARS-Cov-2 isn’t the only virus that Moderna and other pharmaceutical companies, along with health officials, are intent on targeting with more shots. Remember zika virus, which Kennedy described as another pandemic fabricated for the purpose of selling pharmaceuticals and advancing totalitarian control?14 There’s a vaccine on the way.

How about Nipah virus? Nipah virus, a zoonotic pathogen for which no treatments exist, is the inspiration for the film “Contagion.”15 The virus can only be experimented on in BSL-4 laboratories. As an aside, the National Bio and Agro-Defence Facility in Kansas will be the first biocontainment facility16 in the U.S. where research on Nipah (and Ebola) can be conducted on livestock.

In 2019, Nipah Malaysia was also among the deadly virus strains shipped17 from Canada’s National Microbiology Lab to the Wuhan Institute of Virology. If you haven’t heard of Nipah yet, you likely will soon — another vaccine is in the works for it. Bancel said:18,19

“We’re working with Dr. Fauci’s team, we’re working with Richard [Hatchett], to work on many more pathogens … The entire scientific community has known for years that there’s at least around 20-ish pathogens that are a risk for which we need vaccines, you know we have zika vaccine in Phase 2 … we’re working on a Nipah vaccine, those are viruses that not everybody has heard of.

Because we need to have the data. What dose, what construct from a genetic standpoint is required … so that if a new pathogen emerges from that family we can very quickly move into a Phase 3.”

More mRNA Shots Are Coming

Many other vaccines are also under development, including a Phase 3 study looking at combining Pfizer’s COVID-19 injection with their Prevnar 20™ (pneumococcal 20-valent conjugate vaccine) for adults aged 65 and older.20

In a related news release, Kathrin U. Jansen, Ph.D., senior vice president and head of vaccine research and development at Pfizer spoke about the importance of “raising awareness of the importance of adult” vaccinations, echoing Bancel in their desire to create combination shots so adults can get multiple vaccines at one doctor or pharmacy visit.

“As the COVID-19 vaccines and booster doses continue to be administered, we believe that health care providers have an opportunity to talk to their adult patients about other recommended vaccines in line with CDC guidance,” she said.21

An agreement between Pfizer and BioNTech to develop the first mRNA shingles vaccine was also reached in January 2022.22 According to a Pfizer news release, “While there are currently approved vaccines for shingles, there is an opportunity to develop an improved vaccine that potentially shows high efficacy and better tolerability, and is more efficient to produce globally, by utilizing mRNA technology.”23

A Phase 1 study by Moderna for its mRNA Epstein-Barr virus shot is also underway. The first dose of the experimental shot was given to a study subject January 5, 2022,. In a news release, Moderna detailed their intent on rolling out additional mRNA vaccines against a number of additional viruses as well:24

“The start of this Phase 1 study is a significant milestone as we continue to advance mRNA vaccines against latent viruses, which remain in the body for life after infection and can lead to chronic medical conditions. Moderna is committed to developing a portfolio of first-in-class vaccines against latent viruses for which there are no approved vaccines today, including vaccines against CMV [cytomegalovirus], EBV and HIV.

Our research team is working to bring even more vaccines against latent viruses to the clinic. We believe these vaccines could have a profound impact on quality of health for hundreds of millions of people around the world.”

Other mRNA shots also in development include:

  • An mRNA cancer vaccine for non-small cell lung cancer (NSCLC)25
  • mRNA influenza shots, which are under development by several companies, including Pfizer, Moderna, Sanofi and Translate Bio26
  • An mRNA HIV vaccine, one of which is being studied by Moderna in collaboration with the NIH27
  • Various additional mRNA cancer vaccines, including one targeting advanced melanoma — being developed by BioNTech and Regeneron Pharmaceuticals28 — and several being developed by Moderna, targeting melanoma, NSCLC, colorectal cancer and pancreatic cancer29

Ramping Up Production for Billions of Doses

In case there were any doubt that the powers that be intend to use injections as an increasingly integral part of your health care routine and daily life, Bancel described plans for billions of doses of shots to be manufactured in a matter of months. He said during the WEF session:30,31

“The other piece is manufacturing. If you look in 2020, we were able to ship 20 million doses to the U.S. government when the vaccine was authorized. That is not a lot.

But this year we’re going to have 2 to 3 billion doses of capacity in a six-month timeframe, which is what I believe it will take us to get authorization of a vaccine, if all the work has been done before … you could have 1.5 billion doses available in six months, and that’s just from Moderna. And you have other platforms, it could be a much bigger number …”

With censorship now so pervasive, and Big Tech colluding with dictators and pharmaceutical companies to bury the harms occurring through these experimental vaccines — including death — it’s now more important than ever to let your voice be heard in support of medical freedom and opposition of government health officials intimidating, threatening and coercing citizens to violate their conscientiously-held beliefs.

The ethical principal of informed consent to medical risk taking, which includes the legal right to make voluntary decisions about getting experimental injections, must be protected. For now, however, as Eugyppius explained:32

“The vaccinators are a great sword of Damocles over our heads. As I type this, they are scouring the earth for the novel pathogens their products require, and they, together with their bureaucratic and academic allies, will do their level best to call into being new pandemic scares and vaccination campaigns whenever possible — perhaps every flu season.”

Sources and References

February 5, 2022 Posted by | Science and Pseudo-Science, Timeless or most popular | , , , , , | 1 Comment

FDA Grants Full Approval of Moderna’s Spikevax COVID Vaccine — Another ‘Bait-and-Switch?’

By Michael Nevradakis, Ph.D. | The Defender | February 2, 2022

The U.S. Food and Drug Administration (FDA) on Monday granted full approval of Moderna’s Spikevax COVID vaccine for people 18 and older.

Similar to the agency’s licensing last year of Pfizer’s Comirnaty vaccine, the approval raised a number of legal questions related to mandates and product availability.

Spikevax is a two-dose primary series, approved also for administration as part of a heterologous (“mix and match”) single booster dose for individuals who previously completed their original series of vaccinations with the Pfizer or Johnson & Johnson COVID vaccines.

According to the FDA, Spikevax “has the same formulation as the [Emergency Use Authorization (EUA)] Moderna COVID-19 Vaccine and … can be used interchangeably with the EUA Moderna COVID-19 Vaccine to provide the COVID-19 vaccination series.”

However, in its approval letter, the FDA said Spikevax is “legally distinct” from the Moderna EUA vaccine:

“The licensed vaccine has the same formulation as the EUA-authorized vaccine and the products can be used interchangeably to provide the vaccination series without presenting any safety or effectiveness concerns. The products are legally distinct with certain differences that do not impact safety or effectiveness.”

The FDA made the same distinction between the Pfizer-BioNTech EUA vaccine and the Pfizer Comirnaty vaccine, which the agency fully licensed in August, 2021, a move that raised questions about liability and the legality of vaccine mandates.

After Monday’s announcement, media outlets were quick to reassure the public the two Moderna vaccines are the same and that this was just a marketing ploy, where Moderna simply “rebranded” what is otherwise the same vaccine.

No ‘fully licensed’ COVID actually available

While Moderna’s Spikevax vaccine is now fully licensed, the original Moderna vaccine will remain under EUA. Indeed, the FDA on Jan. 7 reissued the EUA.

The FDA has also made it clear the Spikevax vaccine will not be available to the American public, announcing:

“Although SPIKEVAX (COVID-19 Vaccine, mRNA) and Comirnaty (COVID-19 Vaccine, mRNA) are approved to prevent COVID-19 in certain individuals within the scope of the Moderna COVID-19 Vaccine authorization, there is not sufficient approved vaccine available for distribution to this population in its entirety at the time of reissuance of this EUA.”

These claims parallel the chain of events that followed the FDA’s full approval of the Pfizer Comirnaty vaccine in August 2021.

At the time, Pfizer and the FDA claimed Comirnaty was not yet available, as there were sufficient stocks of the Pfizer-BioNTech EUA vaccine still available to be administered.

As of this writing, the FDA states, via its website, that Comirnaty products are “not orderable at this time.”

The FDA has not indicated when, or if, the Spikevax and Comirnaty vaccines will be available for distribution in the U.S.

Are EUA and fully licensed vaccines really interchangeable? 

As reported by The Defender, there is a significant legal distinction between products authorized under EUA and those fully licensed by the FDA.

EUA products are experimental under U.S. law. Under the Nuremberg Code and federal regulations, no one can force a human being to participate in this experiment.

Specifically, under 21 U.S. Code Sec.360bbb-3(e)(1)(A)(ii)(III), “authorization for medical products for use in emergencies,” it is unlawful to deny someone a job or an education because they refuse to be an experimental subject. Instead, potential recipients have an absolute right to refuse EUA vaccines.

That’s an issue military members, unable to find any vaccination sites that offer the fully licensed Comirnaty vaccine, cited in various lawsuits challenging vaccine mandates.

Notably, on Nov. 12, 2021, a federal judge rejected an argument by the U.S. Department of Defense, in defending the military’s vaccine mandate, that the Pfizer Comirnaty and Pfizer-BioNTech vaccines are “interchangeable.”

U.S. law also requires the EUA designation be used only when “there is no adequate, approved and available alternative to the product for diagnosing, preventing or treating such disease or condition.”

This means that, in legal terms, all EUA products should be withdrawn once alternative products have received full approval.

Perhaps the most significant legal distinction, however, pertains to the legal protections afforded vaccine manufacturers, depending on how their product is classified.

Under the 2005 Public Readiness and Preparedness (PREP) Act, EUA-approved vaccines enjoy a significant liability shield. Specifically, vaccine manufacturers, distributors, providers, and government officials involved in the policymaking, approval, and distribution process are immune from any legal liability.

Under such regulations, the only way an injured party can sue is if he or she can prove willful misconduct, and if the U.S. government has also brought an enforcement action against the party for willful misconduct.

No such lawsuit has ever succeeded.

Conversely, fully licensed vaccines, such as Spikevax and Comirnaty, do not have a liability shield, and are instead subject to the same product liability laws as other products.

This means the Spikevax and Comirnaty vaccines could expose pharmaceutical companies to significant financial claims if individuals injured by the vaccines chose to sue the vaccine makers.

The rush to get COVID vaccines authorized for all ages — a ploy to avoid liability? 

There’s another reason Pfizer and Moderna don’t want their fully licensed vaccines to be available yet — they’re waiting for the vaccines to be authorized, then licensed, for children as young as 6 months old.

Why? Because once a vaccine is fully licensed by the FDA, the only way its manufacturer can be shielded from legal liability is if the vaccine is added to the Centers for Disease Control and Prevention’s childhood vaccination schedule.

The National Childhood Vaccine Injury Act (NCVIA), passed into law in 1986, provides a legal liability shield to drugmakers if they receive full authorization for all ages and the vaccine is added to the mandatory schedule.

Reporting on the FDA’s approval of Spikevax, investigative journalist Jordan Schachtel wrote:

“Are Pfizer and Moderna waiting for full authorization for children’s shots to distribute Comirnaty and Spikevax to the masses? There’s plenty of litigators who have suggested that this is exactly what is going on in Big Pharma world.”

By creating the public perception that the Pfizer and Moderna EUA vaccines are fully approved, businesses, schools and other institutions are emboldened to impose vaccine mandates that violate existing law and allow the vaccines to be administered without informed consent.

It has also been argued that by relabeling the product, any previous data regarding vaccine injuries and side effects identified in association with the EUA vaccine are not counted in the safety studies for the approved vaccine.

The FDA approval of the Pfizer Comirnaty vaccine, its subsequent lack of availability and the continued administration of the Pfizer-BioNTech EUA vaccine led Children’s Health Defense (CHD) to file a lawsuit against the FDA and its acting director, Dr. Janet Woodcock, for their allegedly deceptive and rushed approval of the Comirnaty vaccine, arguing that the approval represented a classic “bait and switch” tactic.

CHD further alleged in its lawsuit that the FDA violated federal law when it simultaneously licensed Pfizer’s Comirnaty vaccine and extended Pfizer’s EUA — as the agency has now done with Moderna and Spikevax — for a vaccine that has the “same formulation” and that “can be used interchangeably,” according to the FDA.

FDA admits no safety data for Spikevax use among pregnant women

Beyond the legal questions raised by the FDA’s approval this week of Spikevax, the approval also raises safety questions.

For instance, the FDA admitted Spikevax was insufficiently tested on pregnant women, stating that “[a]vailable data on SPIKEVAX administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.”

Furthermore, Spikevax was approved without having been tested for its ability to provide protection against the Omicron variant, which is reported to account for 99.9% of current U.S. COVID cases — it was approved only for providing protection against mutations that are no longer circulating.

And yet, the FDA cited the Omicron variant as the reason behind its decision to pull its EUA for monoclonal antibody products. The FDA claims that these products have not been shown to provide protection against the Omicron variant.

Michael Nevradakis, Ph.D., is an independent journalist and researcher based in Athens, Greece.

© 2022 Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.

February 3, 2022 Posted by | Deception, Timeless or most popular, War Crimes | , , , , , | Leave a comment

COVID-19: Moderna Gets Its Miracle

BY WHITNEY WEBB | UNLIMITED HANGOUT | OCTOBER 28, 2021

COVID-19 erased the regulatory and trial-related hurdles that Moderna could never surmount before. Yet, how did Moderna know that COVID-19 would create those conditions months before anyone else, and why did they later claim that their vaccine being tested in NIH trials was different than their commercial candidate?

In late 2019, the biopharmaceutical company Moderna was facing a series of challenges that not only threatened its ability to ever take a product to market, and thus turn a profit, but its very existence as a company. There were multiple warning signs that Moderna was essentially another Theranos-style fraud, with many of these signs growing in frequency and severity as the decade drew to a close. Part I of this three-part series explored the disastrous circumstances in which Moderna found itself at that time, with the company’s salvation hinging on the hope of a divine miracle, a “Hail Mary” save of sorts, as stated by one former Moderna employee.

While the COVID-19 crisis that emerged in the first part of 2020 can hardly be described as an act of benevolent divine intervention for most, it certainly can be seen that way from Moderna’s perspective. Key issues for the company, including seemingly insurmountable regulatory hurdles and its inability to advance beyond animal trials with its most promising—and profitable—products, were conveniently wiped away, and not a moment too soon. Since January 2020, the value of Moderna’s stock—which had embarked on a steady decline since its IPO—grew from $18.89 per share to its current value of $339.57 per share, thanks to the success of its COVID-19 vaccine.

Yet, how exactly was Moderna’s “Hail Mary” moment realized, and what were the forces and events that ensured it would make it through the FDA’s emergency use authorization (EUA) process? In examining that question, it becomes quickly apparent that Moderna’s journey of saving grace involved much more than just cutting corners in animal and human trials and federal regulations. Indeed, if we are to believe Moderna executives, it involved supplying formulations for some trial studies that were not the same as their COVID-19 vaccine commercial candidate, despite the data resulting from the former being used to sell Moderna’s vaccine to the public and federal health authorities. Such data was also selectively released at times to align with preplanned stock trades by Moderna executives, turning many of Moderna’s highest-ranking employees into millionaires, and even billionaires, while the COVID-19 crisis meant economic calamity for most Americans.

Not only that, but—as Part II of this three-part series will show, Moderna and a handful of its collaborators at the National Institutes of Health (NIH) seemed to know that Moderna’s miracle had arrived—well before anyone else knew or could have known. Was it really a coincidental mix of “foresight” and “serendipity” that led Moderna and the NIH to plan to develop a COVID-19 vaccine days before the viral sequence was even published and months before a vaccine was even considered necessary for a still unknown disease? If so, why would Moderna—a company clearly on the brink—throw everything into and gamble the entire company on a vaccine project that had no demonstrated need at the time?

The Serendipitous Origins of Moderna’s COVID-19 Vaccine

When early January 2020 brought news of a novel coronavirus outbreak originating in Wuhan, China, Moderna’s CEO Stéphane Bancel immediately emailed Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, and asked to be sent the genetic sequence for what would become known as SAR-CoV-2, allegedly because media reports on the outbreak “troubled” him. The date of that email varies according to different media reports, though most place it as having been sent on either January 6th or 7th.

A few weeks before Bancel’s email to Graham, Moderna was quickly approaching the end of the line, their desperately needed “Hail Mary” still not having materialized. “We were freaked out about money,” Stephen Hoge would later remember of Moderna’s late 2019 circumstances. Not only were executives “cutting back on research and other expenditures” like never before, but – as STAT News would later report – “cash from investors had stopped pouring in and partnerships with some drug makers had been discontinued. In meetings at Moderna, Bancel emphasized the need to stretch every dollar and employees were told to reduce travel and other expenses, a frugality they were advised would last several years.”

At the tail end of 2019, Graham was in a very different mood than Bancel, having emailed the leader of the coronavirus team at his NIH lab saying, “Get ready for 2020,” apparently viewing the news out of Wuhan in late 2019 as a harbinger of something significant. He went on, in the days before he was contacted by Bancel, to “run a drill he had been turning over in his mind for years” and called his long-time colleague Jason McLellan “to talk about the game plan” for getting a head start on producing a vaccine the world did not yet know it needed. When Bancel called Graham soon afterward and asked about this new virus, Graham responded that he didn’t know yet but that “they were ready if it turned out to be a coronavirus.” The Washington Post claimed that Graham’s apparent foreknowledge that a coronavirus vaccine would be needed before anyone officially knew what type of disease was circulating in Wuhan was a fortunate mix of “serendipity and foresight.”

Dr. Barney Graham and Dr. Kizzmekia Corbett, VRC coronavirus vaccine lead, discuss COVID-19 research with Sen. Chris Van Hollen, Sen. Benjamin Cardin and Rep. Jamie Raskin, March 6, 2020; Source: NIH

A report in Boston magazine offers a slightly different account than that reported by the Washington Post. Per that article, Graham had told Bancel, “If [the virus] is a coronavirus, we know what to do and have proven mRNA is effective.” Per that report, this assertion of efficacy from Graham referred to Moderna’s early stage human-trial data published in September 2019 regarding its chikungunya vaccine candidate, which was funded by the Defense Advanced Research Projects Agency (DARPA), as well as its cytomegalovirus (CMV) vaccine candidate.

As mentioned in Part I of this series, the chikungunya vaccine study data released at that time included the participation of just four subjects, three of whom developed significant side effects that led Moderna to state that they would reformulate the vaccine in question and would pause trials on that vaccine candidate. In the case of the CMV vaccine candidate, the data was largely positive, but it was widely noted that the vaccine still needed to pass through larger and longer clinical trials before its efficacy was in fact “proven,” as Graham later claimed. In addition, Graham implied that this early stage trial of Moderna’s CMV vaccine candidate was somehow proof that an mRNA vaccine would be effective against coronaviruses, which makes little sense since CMV is not a coronavirus but instead hails from the family of viruses that includes chickenpox, herpes, and shingles.

Bancel apparently had reached out to Graham because Graham and his team at the NIH had been working in direct partnership with Moderna on vaccines since 2017, soon after Moderna had delayed its Crigler-Najjar and related therapies in favor of vaccines. According to Boston magazine, Moderna had been working closely with Graham specifically “on [Moderna’s] quest to bring a whole new class of vaccines to market” and Graham had personally visited Moderna’s facilities in November 2019. Dr. Anthony Fauci, the director of the NIH’s infectious-disease division NIAID, has called his unit’s collaboration with Moderna, in the years prior to and also during the COVID-19 crisis, “most extraordinary.”

The year 2017, besides being the year when Moderna made its pivot to vaccines (due to its inability to produce safe multidose therapies, see Part I), was also a big year for Graham. That year he and his lab filed a patent for the “2P mutation” technique whereby recombinant coronavirus spike proteins can be stabilized in a prefusion state and used as more effective immunogens. If a coronavirus vaccine were to be produced using this patent, Graham’s team would financially benefit, though federal law caps their annual royalties. Nonetheless, it would still yield a considerable sum for the named researchers, including Graham.

However, due to the well-known difficulties with coronavirus vaccine development, including antibody dependent enhancement risk, it seemed that commercial use of Graham’s patent was a pipe dream. Yet, today, the 2P mutation patent, also known as the ’070 patent, is not just in use in Moderna’s COVID-19 vaccine, but also in the COVID-19 vaccines produced by Johnson & Johnson, Novavax, Pfizer/BioNTech, and CureVac. Experts at New York University School of Law have noted that the 2P mutation patent first filed in 2016 “sounds remarkably prescient” in light of the COVID crisis that emerged a few years later while later publications from the NIH (still pre-COVID) revealed that the NIH’s view on “the breadth and importance of the ’070 patent” as well as its potential commercial applications was also quite prescient, given that there was little justification at the time to hold such a view.

On January 10, three days after the reported initial conversation between Bancel and Graham on the novel coronavirus outbreak in Wuhan, China, Graham met with Hamilton Bennett, the program leader for Moderna’s vaccine portfolio. Graham asked Bennett “if Moderna would be interested in using the new [novel coronavirus] to test the company’s accelerated vaccine-making capabilities.” According to Boston, Graham then mused, “That way . . . if ever there came a day when a new virus emerged that threatened global public health, Moderna and the NIH could know how long it would take them to respond.”

Graham’s “musings” to Bennett are interesting considering his earlier statements made to others, such as “Get ready for 2020” and his team, in collaboration with Moderna, would be “ready if [the virus then circulating in Wuhan, China] turned out to be a coronavirus.” Is this merely “serendipity” and “foresight”, as the Washington Post suggested, or was it something else? It is worth noting that the above accounts are those that have been given by Bancel and Graham themselves, as the actual contents of these critical January 2020 emails have not been publicly released.

When the genetic sequence of SARS-CoV-2 was published on January 11, NIH scientists and Moderna researchers got to work determining which targeted genetic sequence would be used in their vaccine candidate. Later reports, however, claimed that this initial work toward a COVID-19 vaccine was merely intended to be a “demonstration project.”

Other odd features of the Moderna-NIH COVID-19 vaccine-development story emerged with Bancel’s account of the role the World Economic Forum played in shaping his “foresight” when it came to the development of a COVID-19 vaccine back in January 2020. On January 21, 2020, Bancel reportedly began to hear about “a far darker version of the future” at the World Economic Forum (WEF) annual meeting in Davos, Switzerland, where he spent time with “two [anonymous] prominent infectious-disease experts from Europe” who shared with him data from “their contacts on the ground in China, including Wuhan.” That data, per Bancel, showed a dire situation that left his mind “reeling” and led him to conclude, that very day, that “this isn’t going to be SARS. It’s going to be the 1918 flu pandemic.”

Stéphane Bancel speaks at the Breakthroughs in Cancer Care session at WEF annual meeting, January 24, 2020; Source: WEF

This realization is allegedly what led Bancel to contact Moderna cofounder and chairman, as well as a WEF technology pioneer, Noubar Afeyan. Bancel reportedly interrupted Afeyan’s celebration of his daughter’s birthday to tell him “what he’d learned about the virus” and to suggest that “Moderna begin to build the vaccine—for real.” The next day, Moderna held an executive meeting, which Bancel attended remotely, and there was considerable internal debate about whether a vaccine for the novel coronavirus would be needed. To Bancel, the “sheer act of debating” pursuing a vaccine for the virus was “absurd” given that he was now convinced, after a single day at Davos, that “a global pandemic was about to descend like a biblical plague, and whatever distractions the vaccine caused internally at Moderna were irrelevant.”

Bancel spent the rest of his time at the Davos annual meeting “building partnerships, generating excitement, and securing funding,” which led to the Moderna collaboration agreement with the Coalition for Epidemic Preparedness Innovations—a project largely funded by Bill Gates. (Bancel and Moderna’s cozy relationship with the WEF, dating back to 2013, was discussed in Part I as were the Forum’s efforts, beginning well before COVID-19, to promote mRNA-based therapies as essential to the remaking of the health-care sector in the age of the so-called Fourth Industrial Revolution). At the 2020 annual meeting attended by Bancel and others it was noted that a major barrier to the widespread adoption of these and other related “health-care” technologies was “public distrust.” The panel where that issue was specifically discussed was entitled “When Humankind Overrides Evolution.”

As also noted in Part I of this series, a few months earlier, in October 2019, major players in what would become the Moderna COVID-19 vaccine, particularly Rick Bright and Anthony Fauci, had discussed during a Milken Institute panel on vaccines how a “disruptive” event would be needed to push the public to accept “nontraditional” vaccines such as mRNA vaccines; to convince the public that flu-like illnesses are scarier than traditionally believed; and to remove existing bureaucratic safeguards in the vaccine development-and-approval processes.

That panel took place less than two weeks after the Event 201 simulation, jointly hosted by the World Economic Forum, the Bill & Melinda Gates Foundation, and the Johns Hopkins Center for Health Security. Event 201 simulated “an outbreak of a novel zoonotic coronavirus” that was “modeled largely on SARS but . . . more transmissible in the community setting by people with mild symptoms.” The recommendations of the simulation panel were to considerably increase investment in new vaccine technologies and industrial approaches, favoring rapid vaccine development and manufacturing. As mentioned in Part I, the Johns Hopkins Center for Health Security had also conducted the June 2001 Dark Winter simulation that briefly preceded and predicted major aspects of the 2001 anthrax attacks, and some of its participants had apparent foreknowledge of those attacks. Other Dark Winter participants later worked to sabotage the FBI investigation into those attacks after their origin was traced back to a US military source.

It is hard to imagine that Bancel, whose company had long been closely partnered with the World Economic Forum and the Gates Foundation, was unaware of the exercise and surprised by the closely analogous event that transpired within three months. Given the accounts given by Bancel, Graham, and others, it seems likely there is more to the story regarding the origins of Moderna’s early and “serendipitous” push to develop a COVID-19 vaccine. In addition, given that Moderna was in dire financial circumstances at the time, it seems odd that the company would gamble everything on a vaccine project that was opposed by the few investors that were still willing to fund Moderna in January/February 2020. Why would they divert their scant resources towards a project born only out of Barney Graham’s “musings” that Moderna could try to test the speed of its vaccine development capabilities and Bancel’s doomsday view that a “biblical plague” was imminent, especially when their investors opposed the idea?

Moderna Gets to Bypass Its Long-Standing Issues with R & D

Moderna produced the first batch of its COVID-19 vaccine candidate on February 7, one month after Bancel and Graham’s initial conversation. After a sterility test and other mandatory tests, the first batch of its vaccine candidate, called mRNA-1273, shipped to the NIH on February 24. For the first time in a long time, Moderna’s stock price surged. NIH researchers administered the first dose of the candidate into a human volunteer less than a month later, on March 16.

Controversially, in order to begin its human trial on March 16, regulatory agencies had to allow Moderna to bypass major aspects of traditional animal trials, which many experts and commentators noted was highly unusual but was now deemed necessary due to the urgency of the crisis. Instead of developing the vaccine in distinct sequential stages, as is the custom, Moderna “decided to do all of the steps [relating to animal trials] simultaneously.” In other words, confirming that the candidate is working before manufacturing an animal-grade vaccine, conducting animal trials, analyzing the animal-trial data, manufacturing a vaccine for use in human trials, and beginning human trials were all conducted simultaneously by Moderna. Thus, the design of human trials for the Moderna vaccine candidate was not informed by animal-trial data.

Lt. Javier Lopez Coronado and Hospitalman Francisco Velasco inspect a box of COVID-19 vaccine vials at the Naval Health Clinic in Corpus Christi, TX, December 2020; Source: Wikimedia

This should have been a major red flag, given Moderna’s persistent difficulties in getting its products past animal trials. As noted in Part I, up until the COVID-19 crisis, most of Moderna’s experiments and products had only been tested in animals, with only a handful able to make it to human trials. In the case of the Crigler-Najjar therapy that it was forced to indefinitely delay, toxicity concerns related to the mRNA delivery system being used had emerged in the animal trials, which Moderna was now greenlighted to largely skip. Given that Moderna had subsequently been forced to abandon all multidose products because of poor results in animal trials, being allowed to skip this formerly insurmountable obstacle was likely seen as a boon to some at the company. It is also astounding that, given Moderna’s history with problematic animal trials, more scrutiny was not devoted to the regulatory decision to allow Moderna to essentially skip such trials.

Animal studies conducted on Moderna’s COVID-19 vaccine did identify problems that should have informed human trials, but this did not happen because of the regulatory decision. For example, animal reproductive toxicity studies on the Moderna COVID-19 vaccine that are cited by the European Medicines Agency found that there was reduced fertility in rats that received the vaccine (e. g., overall pregnancy index of 84.1% in vaccinated rats versus 93.2% in the unvaccinated) as well as an increased proportion of aberrant bone development in their fetuses. That study has been criticized for failing to report on the accumulation of vaccine in the placenta as well as failing to investigate the effect of vaccine doses administered during key pregnancy milestones, such as embryonic organogenesis. In addition, the number of animals tested is unstated, making the statistical power of the study unknown. At the very least, the 9 percent drop in the fertility index among vaccinated rats should have prompted expanded animal trials to investigate concerns of reproductive toxicity before testing in humans.

Yet, Moderna declined to further investigate reproductive toxicity in animal trials and entirely excluded reproductive toxicity studies from its simultaneous human trials, as pregnant women were excluded from participation in the clinical trials of its vaccine. Despite this, pregnant women were labeled a priority group for receiving the vaccine after Emergency Use Authorization (EUA) was granted for the Moderna and Pfizer/BioNTech vaccines. Per the New England Journal of Medicine, this meant that “pregnant women and their clinicians were left to weigh the documented risks of Covid-19 infection against the unknown safety risks of vaccination in deciding whether to receive the vaccine.”

Moderna only began recruiting for an “observational pregnancy outcome study” of its COVID-19 vaccine in humans in mid-July 2021, and that study is projected to conclude in early 2024. Nevertheless, the Centers for Disease Control recommends the use of Moderna’s COVID-19 vaccine in “people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future.” This recommendation is largely based on the CDC’s publication of preliminary data on mRNA COVID-19 vaccine safety in pregnant women in June 2021, which is based on passive reporting systems in use within the United States (i. e., VAERS and v-safe).

Even in the limited scope of this study, 115 of the 827 women who had a completed pregnancy during the study lost the baby, 104 of which were spontaneous abortions before 20 weeks of gestation. Of these 827 pregnant women, only 127 had received a mRNA vaccine before the 3rd trimester. This appears to suggest an increased risk among those women who took the vaccine before the 3rd trimester, but the selective nature of the data makes it difficult to draw any definitive conclusions. Despite claims from the New England Journal of Medicine that the study’s data was “reassuring”, the study’s authors ultimately stated that their study, which mainly looked at women who began vaccination in the third trimester, was unable to draw “conclusions about spontaneous abortions, congenital anomalies, and other potential rare neonatal outcomes.” This is just one example of the problems caused by “cutting corners” with respect to Moderna’s COVID-19 vaccine trials in humans and animals, including those conducted by the NIH.

Meanwhile, throughout February, March and April, Bancel was “begging for money” as Moderna reportedly lacked “enough money to buy essential ingredients for the shots” and “needed hundreds of millions of dollars, perhaps even more than a billion dollars” to manufacture its vaccine, which had only recently begun trials. Bancel, whose tenure at Moderna had long been marked by his ability to charm investors, kept coming up empty-handed.

Then, in mid-April 2020, Moderna’s long-time cooperation with the US government again paid off when Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) awarded the company $483 million to “accelerate the development of its vaccine candidate for the novel coronavirus.” A year later, the amount invested in Moderna’s COVID-19 vaccine by the US government had grown to about $6 billion dollars, just $1.5 billion short of the company’s entire value at the time of its pre-COVID IPO.

BARDA, throughout 2020, was directly overseen by the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), led by the extremely corrupt Robert Kadlec, who had spent roughly the last two decades designing BARDA and helping shape legislation that concentrated many of the emergency powers of HHS under the Office of the ASPR. Conveniently, Kadlec occupied the powerful role of ASPR that he had spent years sculpting at the exact moment when the pandemic, which he had simulated the previous year via Crimson Contagion, took place. As mentioned in Part I, he was also a key participant in the June 2001 Dark Winter exercise. In his capacity as ASPR during 2020, Kadlec oversaw nearly all major aspects of the HHS COVID-19 response and had a key role in BARDA’s funding decisions during that period, as well as in the affairs of the NIH and the Food and Drug Administration as they related to COVID-19 medical countermeasures, including vaccines.

On May 1, 2020, Moderna announced a ten-year manufacturing agreement with the Lonza Group, a multinational chemical and biotech company based in Switzerland. Per the agreement, Lonza would build out vaccine production sites for Moderna’s COVID-19 vaccine, first in the US and Switzerland, before expanding to Lonza’s facilities in other countries. The scale of production discussed in the agreement was to produce 1 billion doses of Moderna’s COVID-19 vaccine annually. It was claimed that the ten-year agreement would also focus on other products, even though it was well known at the time that other Moderna products were “nowhere close to being ready for the market.” Moderna executives would later state that they were still scrambling for the cash to manufacture doses at the time the agreement with Lonza was made.

The decision to forge a partnership to produce that quantity of doses annually suggests marvelous foresight on the part of Moderna and Lonza that the COVID-19 vaccine would become an annual or semiannual affair, given that current claims of waning immunity could not have been known back then because initial trials of the Moderna vaccine had begun less than two months earlier and there was still no published data on its efficacy or safety. However, as will be discussed Part III of this series, Moderna needs to sell “pandemic level” quantities of its COVID-19 vaccine every year in order to avoid a return of the existential crises it faced before COVID-19 (for more on those crises, see Part I). The implications of this, given Moderna’s previous inability to produce a safe product for multidosing and lack of evidence that past issues were addressed in the development of its COVID-19 vaccine, will also be discussed in Part III of this series.

It is also noteworthy that, like Moderna, Lonza as a company and its leaders are closely affiliated with the World Economic Forum. In addition, at the time the agreement was reached in May 2020, Moncef Slaoui, the former GlaxoSmithKline executive, served on the boards of both Moderna and Lonza. Slaoui withdrew from the boards of both companies two weeks after the agreement was reached to become the head of the US-led vaccination-development drive Operation Warp Speed. Moderna praised Slaoui’s appointment to head the vaccination project.

By mid-May, Moderna’s stock price—whose steady decline before COVID-19 was detailed in Part I —had tripled since late February 2020, all on high hopes for its COVID-19 vaccine. Since Moderna’s stock had begun to surge in February, media reports noted that “nearly every progress update—or media appearance by Moderna CEO Stephane Bancel—has been gobbled up by investors, who seem to have an insatiable appetite for the stock.” Bancel’s tried-and-tested method of keeping Moderna afloat on pure hype, though it was faltering before COVID-19, was again paying off for the company thanks to the global crisis and related panic.

Some critics did emerge, however, calling Moderna’s now $23 billion valuation “insane,” especially considering that the company had posted a net loss of $514 million the previous year and had yet to produce a safe or effective medicine since its founding a decade earlier. In January 2020, Moderna had been worth a mere $5 billion, $2 billion less than its valuation at its December 2018 IPO. If it hadn’t been for the onset of the COVID crisis and a fresh injection of hype, it seems that Moderna’s valuation would have continued to shrink. Yet, thankfully for Moderna, investors were valuing Moderna’s COVID-19 vaccine even before the release of any clinical data. Market analysts at the time were forecasting Moderna’s 2022 revenue at about $1 billion, a figure based almost entirely on coronavirus vaccine sales, since all other Moderna products were years away from a market debut. Yet, even with this forecasted revenue, Moderna’s stock value in mid-May 2020 was trading at twenty-three times its projected sales, a phenomenon unique to Moderna among biotech stocks at the time. For comparison, the other highest multiples in biotech at the time were Vertex Pharmaceutical and Seattle Genetics, which were then trading at nine and twelve times their projected revenue, respectively. Now, with the implementation of booster shot policies around the world, revenue forecasts for Moderna now predict the company will make a staggering $35 billion in COVID-19 vaccine sales through next year.

Moderna’s surging stock price went into overdrive when, on May 18, 2020, the company published “positive” interim data for a phase 1 trial of its COVID-19 vaccine. The results generated great press, public enthusiasm, and a 20 percent boost in Moderna’s stock price. Just hours after the press release, Moderna announced a new effort to raise $1.3 billion by selling more stock. It has since been revealed that Moderna had hired Morgan Stanley to manage that stock sale on May 15.

However, left largely unmentioned by the press or Moderna itself was that the ostensibly “scientific study” only provided data from 8 of the 45 volunteers—4 volunteers each from the 15- and 100-microgram dose cohorts—regarding the development of neutralizing antibodies. The age of these mysteriously selected 8 volunteers was also not published, and other key data was missing, making it “impossible to know whether mRNA-1273 [Moderna’s COVID-19 vaccine] was ineffective [in the remaining 37 volunteers whose antibody data was not disclosed], or whether the results were not available at this point.” Meanwhile, in the highest-dose cohort, in which volunteers received 250 micrograms, 21 percent of volunteers experienced a grade 3 adverse event, which is defined by the FDA as “preventing daily activity and requiring medical intervention.”

STAT published a report the next day that was skeptical of Moderna’s press release and seemed to imply the data release was aimed at boosting the company’s stock valuation, which hit $29 billion after the news. STAT reporter Helen Branswell called this jump in valuation “an astonishing feat for a company that currently sells zero products.” Branswell’s report noted several things, including that several vaccine experts had noted that “based on the information made available [by Moderna], there’s really no way to know how impressive—or not—the vaccine may be.” Moderna later defended its withholding of key data in the press release, claiming that it was done to respect “federal securities laws and the rules of scientific journals” and to prevent a potential leak of the data from insiders at the NIH. Moderna executives have more recently claimed that the “timely” release of these selective data had been linked to their “desperate” fundraising efforts at the time and ultimately prevented them from “losing” the COVID-19 vaccine race.

The STAT report also noted that the National Institute of Allergy and Infectious Diseases (NIAID), which was running the trial referenced by Moderna in the press release, was completely silent on the matter, declining to put out a press release that day and declining to comment on Moderna’s announcement. This was described as uncharacteristic for NIAID, especially considering they were the part of the NIH co-developing the vaccine with Moderna and running the trial. STAT noted that, normally, “NIAID doesn’t hide its light under a bushel. The institute generally trumpets its findings.” In this case, however, they declined to do so. It emerged in early June 2020 that Dr. Anthony Fauci, who leads NIAID, had been displeased with Moderna’s decision to publish incomplete data on the trial, telling STAT that he would have preferred “to wait until we had the data from the entire Phase 1 . . . and publish it in a reputable journal and show all the data.”

Tal Zaks, Chief Scientific Officer at Moderna; Source: The Forward

It subsequently emerged that Moderna’s top executives, including chief financial officer Lorence Kim and chief scientific officer Tal Zaks, had used their insider knowledge of the coming press release to trade company stock that netted them several million each following the jump in Moderna’s stock that resulted from the press release’s positive buzz. A little over a week after the press release had been published, STAT reported that the top five Moderna executives had cashed out $89 million in shares since the company’s stock price had begun to soar earlier in the year. Per that report, the amount of trades by these five executives alone between January and May 2020 was “nearly three times as many stock transactions than in all of 2019.” By September 2020, the amount of stock shed by Moderna executives amounted to $236 million. Less criticized or even mentioned by the press was Moderna’s move, less than a month later, to create a tax haven in Europe for its European COVID-19 vaccine sales.

Though the trades were deemed slimy but legal, mainstream media reports essentially confirmed that the early release of the interim data was planned to “raise the share price of Moderna’s stock so that executives could cash in during the period of euphoria” that followed. Some watchdog groups called on the SEC to investigate Moderna executives for manipulating the stock market. The critical reporting on executive stock trades and Moderna’s release of incomplete data led the company’s stock to temporarily trend downward throughout the rest of May. As previously mentioned, Moderna has repeatedly attempted to explain away the timing of this particular press release, offering new explanations as recently as this week.

Moderna’s Shocking Claim about Its Vaccine Candidate

In mid-June 2020, researchers at the NIH and Moderna published a manuscript preprint of preclinical data for Moderna’s COVID-19 vaccine. This preprint described the vaccine as employing a delivery system covered in a patent owned by the company Arbutus Biopharma and described the results of that vaccine in tests on mice. As discussed in Part I, Moderna has long been locked in a bitter legal dispute with Arbutus, which has threatened Moderna’s ability to ever turn a profit on any product that relies on Arbutus-patented technology regarding lipid nanoparticle (LNP) delivery systems for its mRNA products. Moderna has claimed for years it was no longer using the Arbutus-derived system on which it once entirely relied, with Bancel even going so far as to publicly call it “not very good.” However, Moderna has provided no real evidence that it no longer relies on the technology covered in the Arbutus patents. The June 2020 manuscript preprint from the NIH and Moderna provided evidence indicating that the same Arbutus-derived technology that had caused major toxicity issues in multidose products Moderna had previously attempted to develop was also being used in Moderna’s COVID-19 vaccine candidate.

Yet, when Moderna’s chief corporate affairs officer, Ray Jordan, was challenged on this point by Forbes, Jordan asserted that the preprint’s data had been generated using a formulation of a COVID-19 vaccine that is not the same as the vaccine itself, stating, “While the authors of the preprint used the term ‘mRNA-1273’ for convenience of the reader, the preprint does not describe the cGMP process by which we make our messenger RNA and LNP or the final drug product composition in our commercial candidate (mRNA-1273).” When Forbes asked Jordan if he could provide any specifics, including the LNP molar ratio of the new LNP technology to prove that the LNPs in use in the COVID-19 vaccine were in fact different from those covered by the Arbutus patent, Jordan flat out refused.

Arbutus Biopharma’s office in Warminster, Pennsylvania; Source: Philadelphia Business Journal

Despite Jordan’s claims, a Moderna preclinical study regarding its COVID-19 vaccine was published a month later, and that July study noted that the Moderna vaccine used LNPs as described in a 2019 paper, which in turn reveals that the LNPs in question were the same as those used in the June study. This paper included the results from the study originally promoted by Moderna in May that led to a jump in Moderna’s stock price. Now published in full, the study generated lots of positive press, including a statement from the NIAID’s Fauci that “no matter how you slice this, this is good news.” A jump in US government funding of Moderna’s COVID-19 vaccine also shortly followed the study’s publication. At the time, CBS News remarked that Moderna’s stock price, which had been sliding since its late 2018 IPO, had been essentially rescued by the COVID-19 crisis, as “shares of Moderna—which has never brought a product to market over its ten-year existence—have soared as much as 380 percent since the start of the year as news emerged [in January] of its promising potential for producing a vaccine. [Moderna’s] stock price was less than $20 in early January and around $95 on Friday [July 17, 2020].” Today, by comparison, Moderna has consistently been trading above $300 a share.

Yet, if we take Ray Jordan at his word with respect to the preprint published in June, Moderna appears to have been engaged in rather slimy behavior. If Jordan was telling the truth, it appears that this July study, which appears to use the vaccine candidate containing the same LNPs as those described in the June 2020 preprint, also used a formulation not consistent with the company’s commercial vaccine candidate. If so, given that the July study was the same study referenced by Moderna’s controversial May press release tied to insider stock trades, Moderna appears to have used “positive” data generated by a vaccine candidate other than its commercial vaccine candidate to boost stock prices and ameliorate the company’s financial situation while also generating millions for executives. This, of course, says nothing about the separate but critically important issue that the vaccine candidate used in these studies, including the NIH study, is not necessarily the same as the commercial candidate used in clinical trials.

It seems that the only reason that Moderna would make such an outrageous claim to Forbes would be to distance its COVID-19 vaccine from its past controversies that largely have their root in Moderna’s LNP-related problems, which it had claimed to have already resolved. It is not clear if the motive behind such a gambit is principally related to the legal dispute with Arbutus or the past safety issues Moderna encountered with multidose therapies.

Adding to the confusion about the LNPs in use in Moderna’s products is that, a few days earlier in July, Moderna had published results on a separate vaccine candidate, this one for HIV, that appeared to use the exact same LNP technology that is covered by the Arbutus patent. The LNPs described in that study included the same components as those described in the Arbutus patent and the same molar ratio. Moderna appeared to be referencing this issue in their August 6, 2020, SEC filing, which states: “There are many issued and pending third-party patents that claim aspects of oligonucleotide delivery technologies that we may need for our mRNA therapeutic and vaccine candidates or marketed products, including mRNA-1273, if approved.”

By the end of 2020, Moderna claimed in a December filing with the SEC that, while it had “initially used LNP formulations that were based on known lipid systems,” that is, the Arbutus LNPs, it had “invested heavily in delivery science and ha[s] developed LNP technologies, as well as alternative nanoparticle approaches.” Despite the claims it made in this filing, however, it remained unclear as to whether the company’s COVID-19 vaccine was using Arbutus technology or the technology it purported to have developed on its own without infringing on Arbutus’s intellectual property.

Moderna’s claims that it now uses a different LNP system than the one that caused such major issues is based on the company’s development and implementation of a lipid structure now known as SM-102. This lipid structure was first revealed by Moderna in a 2019 publication under the name Lipid H, and, in that paper and since, Moderna has claimed that its LNP system is now superior to that which it previously used because it is using SM-102 instead of the original Arbutus lipids. However, it is critical to note that Moderna’s use of SM-102 does not necessarily mean the company is not violating the Arbutus patents, which cover the use of LNPs that combine cationic and PEGylated lipids in specific proportions.

Despite claims from Moderna that SM-102 resolved both the company’s patent-related and toxicity issues with its LNP system (as discussed in Part I), Moderna has declined to disclose SM-102’s exact structure or whether it carries a net positive charge at physiological pH, the latter of which could lead to proof of continued infringement on the Arbutus patent. In addition, there are no studies on the distribution, degradation, and/or elimination of SM-102 from the body, meaning that the accumulation of the lipids or their capacity to damage organs is not documented. The obvious lack of study of SM-102’s properties and effects on the human body was largely circumvented by public health authorities during the emergency approval process by using the same criteria for the Moderna vaccine candidate that is used for traditional vaccines that do not utilize the novel mRNA approach. These “traditional” criteria therefore do not include any requirements for data on LNP safety.

Overall, the evidence seems to point toward Moderna’s claims that its COVID-19 vaccine doesn’t use Arbutus-derived LNPs as being false. The other possibility is that Moderna attempted to modify the LNP system but only slightly so that potential identifiers, such as the molar ratio, remained the same. In this case, Arbutus could still claim that the LNPs currently in use by Moderna and in its COVID-19 vaccine infringe on their patent. It is also thus likely that the safety issues Moderna had acknowledged with this LNP system were largely unaffected if the potential modifications were indeed minor. Yet, if either of these scenarios is correct, the question becomes – Why wouldn’t Arbutus challenge Moderna once again to obtain royalty payments stemming from its COVID-19 vaccine?

The answer seems to lie mostly in optics and public relations. As STAT wrote last July, were Arbutus to sue Moderna over patent infringement in the midst of the COVID-19 crisis, “that would mean taking the substantial risk that it would be perceived as a company holding up a desperately needed medicine out of concern for its bottom line.” This also seemed to be part of the motive behind Moderna’s altruistically framed promise not to enforce its own COVID-19–related patents until the pandemic is declared over. Observers have noted that this move by Moderna was not only a public relations boon for the company but also “set a disarming tone in the space that may serve to deter others in the space [e. g., Arbutus] from acting too defensively or aggressively,” largely due to “fear of the potential public relations backlash.”

While July 2020 brought a surge in valuation and positive press for Moderna and its COVID-19 vaccine candidate, it also brought an unfavorable ruling for Moderna in its long-running dispute with Arbutus, one that opened the door for Arbutus to file an injunction against Moderna’s COVID-19 vaccine, if they chose, to force the negotiation of a license with Moderna. The news led to Moderna’s stock price falling by 10 percent, wiping out $3 billion in value. However, most likely for the reasons outlined above, Arbutus ultimately declined to jump on the decision to block Moderna’s COVID-19 vaccine from advancing in the hopes of securing royalties. Yet, they reserve the ability to do so, if and when the perceived urgency of the COVID-19 crisis fades.

Moderna has asserted that the decision would not affect its COVID-19 vaccine as the company was “not aware of any significant intellectual property impediments for any products we intend to commercialize.” Thus, Ray Jordan’s assertions and the lack of “clear and convincing” evidence that Moderna’s COVID-19 vaccine relies on Arbutus-patented technology appears to have been sufficient for Moderna to make this claim. This seems to be due to a lack of interest by the mainstream media or federal agencies/regulators in demanding concrete evidence that Moderna’s LNP system used in its COVID-19 vaccine does not rely on Arbutus-patented technology.

Despite the issues raised above in relation to the vaccine study data published in June and July, the positive press attention—particularly after the July publication—translated just a month later into the US government entering into a significant supply agreement with Moderna on August 11, 2020. Per that agreement, the government would pay $1.525 billion for 100 million doses with the option to purchase an additional 400 million doses in the future, all of which it has since purchased. Per Moderna’s press release, the agreement meant that the US government had, by that point, paid $2.48 billion for “early access” to Moderna’s COVID-19 vaccine.

Roughly a month later, it was revealed that the US government had been paying for much more. On September 10, 2020, BARDA joined long-time Moderna funder and “strategic ally” DARPA in scrutinizing contracts that had been awarded to the company due to Moderna’s failure to disclose the role government support had played in its numerous patent applications. The announcement came after Knowledge Ecology International (KEI), which advocates for protecting taxpayer investments in patents, found that none of the patents or applications assigned to Moderna in the company’s entire history had disclosed the considerable US government funding it had received at the time those patents were filed, which is required by the 1980 Bayh-Doyle Act and by the regulations of the Patent and Trademark Office. Per KEI, this translates into the US government owning certain rights over the patents, and thus US taxpayers may have an ownership stake in vaccines made and sold by Moderna.

Despite the clear evidence that Moderna failed to disclose the considerable amount of US government funding prior to and during the COVID crisis in its patent applications, Moderna responded to KEI and the BARDA/DARPA “scrutiny” by stating that it was “aware of and consults with our agency collaborators regarding our contractual obligations under each of these agreements, including those with respect to IP [intellectual property], and believe we comply with those obligations.” As of the writing of this article, BARDA and DARPA have taken no action against Moderna for their illegal omission about having received substantial government funding in their patent applications and filings. Instead, a month after DARPA claimed to be “scrutinizing” Moderna’s patent applications, it awarded the company up to $56 million to develop small-scale mobile means of manufacturing its products—namely, its COVID-19 vaccine and its personalized cancer vaccine.

Moderna: “Just Trust Us” 

What quickly stands out about Moderna’s COVID-19 vaccine candidate over the course of its rapid development in 2020 was the willingness of federal agencies like NIH, BARDA, and others, as well as the mainstream press, to take Moderna at its word concerning critical aspects of its vaccine and its development, even when the evidence appeared to contradict its claims. This is particularly evident in Moderna claiming that it resolved its LNP issues, both in terms of toxicity and patent infringement, and those claims—despite the company’s refusal to release clear supporting evidence—being taken at face value. This is even more striking when one considers the multiple factors that Moderna was facing before COVID-19 and how the company faced collapse without the success of its COVID-19 vaccine, as this means Moderna was under considerable pressure to have its vaccine succeed.

While the controversial simultaneous conducting of animal and human trials was publicly justified in the name of the urgency of the COVID-19 crisis, can the other examples explored in this article be similarly justified in the name of urgency? Instead, several issues explored above appear to have been driven by conflicts of interest and corruption.

Adding to the ridiculousness is that Moderna got away with claiming that the NIH was conducting safety tests on a COVID-19 vaccine product different from their commercial candidate, without causing a major backlash in either the mainstream media or from the NIH itself. This is particularly telling as the May 2020 press release and suspiciously timed stock trading by Moderna executives and insiders did garner negative press attention. However, the subsequent revelation, per Moderna, that its press release was based on the study of a vaccine candidate that was not “necessarily the same” as their commercial COVID-19 vaccine candidate received essentially no coverage, despite raising the unsettling possibility that Moderna could have used another product to essentially rig preliminary data to be positive in order to advance their product to market and make millions through insider stock sales. How can the claims made by such a company be trusted at face value without independent verification? Furthermore, how can NIH studies of Moderna be trusted when Moderna has claimed that some of the studies that were ultimately factors in the vaccine’s emergency use authorization approval by the FDA utilized a different product than that which Moderna later successfully commercialized?

Moderna and the NIH were, nevertheless, taken at their word in November 2020 when they said that their COVID-19 vaccine candidate was 94.5 percent effective. At the time, the main promoters of this claim were Moderna’s Bancel and NIAID’s Fauci. The claim came shortly after Pfizer’s press release claiming its COVID-19 vaccine candidate was 90 percent effective. Not to be outdone by Moderna, Pfizer revised the reported efficacy of its vaccine just two days after Moderna’s November press release, stating that their vaccine was actually 95% effective to Moderna’s 94.5%. In the case of these claims, it was indicative of the now-established yet troubling practice of “science by press release” when it comes to touting the benefit of certain COVID-19 vaccines currently on the market. Since then, real-world data has shattered the efficacy claims that were used to secure emergency use authorization, for which Moderna applied at the end of November 2020 and received only a few weeks later in mid-December of that year.

As Part III of this series will explore, the EUA for the Moderna vaccine got around the issues raised in this article by treating the entire Moderna formulation as a traditional vaccine, which it is not, as traditional vaccines do not utilize mRNA for inducing immunity, and their safety and efficacy depend on several criteria that are entirely different from those of the more novel mRNA. Thus, the LNP issue, a perpetually sticky one for Moderna that it struggled to circumvent before the onset of the COVID-19 crisis, was largely evaded when it came down to, not just research and development, but receiving EUA. It appears that this sleight-of-hand by federal regulators was necessary for Moderna, after ten years, to finally get its first product on the market. As noted in Part I, were it not for the COVID-19 crisis and its fortuitous timing, Moderna might not have survived the severe challenges that threatened its entire existence as a company.

Part III will also examine how Moderna’s “Hail Mary” moment in the COVID-19 crisis was only the beginning of its miraculous rescue from a Theranos-like fate, as the company has not only expanded its partnership with the government but now with a CIA-linked firm. This shows that Moderna and key power players in Big Pharma and the US national-security state envision Moderna’s COVID-19 vaccine being sold in massive quantities for several years to come. As previously noted, without annual or semiannual sales of booster doses, Moderna’s pre-COVID crisis will inevitably return. The push for Moderna booster-dose approval has advanced despite real-world data not supporting Moderna’s past claims of safety and efficacy for its COVID-19 vaccine, the recent decision of several European governments to halt the vaccine’s use, and the FDA’s own infighting and recent admissions that the Moderna COVID-19 vaccine is one of the more dangerous currently in use, particularly in terms of adverse effects on the cardiovascular system. The obvious question here then becomes – How costly will Moderna’s “Hail Mary” save ultimately be, not just in terms of the $6 billion US taxpayer money already spent on it, but also in terms of public health?

November 24, 2021 Posted by | Corruption, Deception, Timeless or most popular | , , , , , , , | 1 Comment

It All Makes Sense Once You Realize They Want to Kill Us

By MIKE WHITNEY • UNZ REVIEW • OCTOBER 17, 2021

“It is now apparent that these products in the blood stream are toxic to humans. An immediate halt to the vaccination programme is required while an independent safety analysis is undertaken to investigate the full extent of the harms, which the UK Yellow Card data suggest includes thromboembolism, multi-system inflammatory disease, immune suppression, autoimmunity and anaphylaxis, as well as Antibody Dependent Enhancement (ADE).” Tess Lawrie, Evidence-Based Medicine Consultancy

“For we wrestle not against flesh and blood, but against the rulers of the darkness of this world, against spiritual wickedness in high places.” Ephesians 6:12

Question – Have the mRNA vaccines been tested on animals?

Answer – Yes, they have.

Question – Were the animal trials successful?

Answer – Yes and no.

Yes, the experiments on mice showed that a low dose of the vaccine induces a robust antibody response to the infection.

But, no, the antibodies were not able to attack the spike protein from a different strain of the virus.

Question – I’m not sure what that means? Do you mean that the vaccine DOES provide some limited protection from the original (Wuhan) virus, but does not necessarily provide protection from the variants?

Answer – That’s right, but it’s a bit more complicated than that because– as the virus changes — the antibodies that helped to fight the original virus can actually enhance the “infectivity” of the variant. In other words, vaccine-generated antibodies can switch-sides and increase the severity of the illness. Simply put, they can make you sicker or kill you. Scientists have known this for a long time. Check out this clip from a 2005 research paper:

“A jab against one strain might worsen infection with others….

In the.. study, Gary Nabel of the National Institute of Allergy and Infectious Diseases.. injected mice with spike protein from a SARS virus taken from a human patient infected in early 2003. They then collected the antibodies the animals produced.

In lab experiments, they showed that these antibodies were unable to attack spike protein from a different strain of SARS, isolated from a patient infected in late 2003…. The team next tested whether the antibodies would attack spike proteins from two SARS strains isolated from civets, from which the virus is thought to have originally jumped into humans. In this case, they found hints that the antibodies actually boosted the ability of the virus to infect cells. …

The results show that the virus changes over time, so that a strain that crops up in one outbreak might be quite different from that in a later outbreak. “This virus is not standing still and we need to take this into account,” Nabel says.

This raises the prospect that a vaccine against one strain of SARS virus could prove ineffective against others. Worse, a jab against one strain might even aggravate an infection with SARS virus from civets or another species. “It’s obviously a concern,” Nabel says..
This would not be the first case where exposure to one strain of a virus can worsen infection with another.” (“Caution raised over SARS vaccine”, Nature )

Question – I’m still confused. Can you summarize what they’re saying?

Answer – Sure. They’re saying that scientists have known for nearly two decades that vaccines narrowly aimed at just one protein are bound to fail. They’re saying that the spike protein is highly-adaptable and capable of changing its shape to survive. They’re saying that vaccines aimed at the spike protein will inevitably produce variants that evade vaccine-generated antibodies. They’re saying that by narrowing the vaccine’s focus to the spike protein alone, the drug companies have ensured that previously helpful antibodies will do an about-face, allow the virus to enter healthy cells, replicate at will, and cause sickness or death. They are saying that the current crop of vaccines is in fact perpetuating the pandemic. And–since the science has been clear for the last 16 years– we can add one more observation to the list, that is, that the current approach to mass vaccination is neither haphazard, slapdash or random. It is intentional. The vaccination campaign managers are deliberately ignoring the science in order to sustain a permanent state of crisis. Science is being manipulated to achieve a political objective.

Question – I think you’re exaggerating, but I’d like to get back to the animal trials instead of arguing politics. As you probably know, the reports in the media do not square with your analysis, in fact, all of the articles in the MSM say the animal trials were a rousing success. Here’s a short blurb that I found today that confirms what I’ve been saying:

“… vaccination of nonhuman primates with the mRNA vaccine induced robust SARS-CoV-2 neutralizing activity and notably, rapid protection in the upper and lower airways….” (Covid-19, NIH.gov)

Question – Are you suggesting the authors are lying?

Answer – No, they are not lying. They’re just not telling you the whole truth, and you need to know the whole truth so you can make an informed decision. The vaccines DO provide some (temporary) protection. We don’t dispute that. They also trigger a strong immune response. We don’t dispute that either. But what difference does it make? Let me explain: Let’s say, you have a really bad head cold so you take a new medication that you think will relieve the pain. And–sure enough– an hour after taking the pills– Presto — your congestion and headache are completely gone. That’s fantastic, right? Wrong, because what you fail to realize is that the medication is laced with slow-acting strychnine that kills you three days later. Do you still think it was a good idea to take the medication?

Of course, not. And the same rule applies to these vaccines which do, in fact, boost your antibodies and provide some fleeting “immunity”. But they can also kill you. Don’t you think that should be factored in to your decision? Keep in mind, people have died 3, 4, 5 weeks after inoculation without any prior warning. Many of them might have even been bursting with antibodies, but they’re still dead. Can you see the problem?

Question – Okay, but there’s still this matter about the animal trials. The media says that the drug companies performed the animal trials and they were successful. Do you disagree with that?

Answer – They were not successful and the “fact checkers” that were hired to discredit vaccine critics like me, have deliberately mischaracterized what happened in the trials. For example, here’s a typical “fact checker” article titled “COVID-19 vaccines did not skip animal trials because of animal deaths” by Reuters. Here’s an excerpt:

“Posts claiming that COVID-19 vaccine producers skipped animal trials due to the animals in those trials dying are false. Pfizer-BioNTech, Moderna and Johnson & Johnson, which have been granted emergency authorization use by the Food and Drug Administration (FDA) in the United States, all conducted animal trials and had no significant safety concerns to report.”

Sounds reassuring, right? But then they say:

“Due to time constraints and the urgency to find a vaccine for COVID-19, Moderna and Pfizer did receive approval to run animal testing and early trials on humans at the same time, as opposed to fully completing animal trials before moving on to human trials. This, however, does not mean animal trials were skipped or that the safety of the vaccines were compromised.”

Let me see if I got this straight: The drug companies were in such a hurry that they conducted their minimalist animal trials at the same time as their human trials (which is unprecedented) and then rushed the results to the FDA so they could be rubber stamped and waved through under the Emergency Use Authority?

Is that how it went down?

Yes, it is.

But if they were rushed through in a couple months, then the “fact checkers” are tacitly admitting that there is no long-term safety data. And there IS no long-term safety data, nor is there any attempt to disprove the research from the earlier trials where the ferrets, mice and other animals died following injection of mRNA vaccines. They don’t deny it, they just ignore it as if sweeping it under the rug will make it all go away. Here’s a clip from the research paper that Reuters refers to in its article:

“We demonstrate that the candidate vaccines… respectively—induce strong antigen-specific immune responses in mice and macaques….Both (vaccines) protected 2–4-year-old macaques from challenge with infectious SARS-CoV-2, and there was reduced detection of viral RNA in immunized macaques as compared to those that received saline.” (Note–We’ve already acknowledged that the vaccines do produce a strong immune response. Here’s more:)

“Neutralizing GMTs declined by day 56 (35 days after dose 2), consistent with the contraction phase; however, they remained well above the GMT of the human sera panel. The duration of the study was not long enough to assess the rate of decline during the plateau phase of the antibody response.” (“BNT162b vaccines protect rhesus macaques from SARS-CoV-2”, Nature )

Can you see what’s going on? The trial was only 56 days-long, in fact, none of the animal trials exceeded 56 days. Think about that for a minute. The reason the animals died in prior trials is because they were exposed to a mutated version of the (wild) virus that eventually killed them. That’s how ADE (antibody-dependent enhancement) works. It doesn’t happen overnight and it doesn’t happen in 56 days. It takes much longer than that for a mutated version of the virus to emerge and reinfect the host. The drug companies know that. They’re not stupid. So the fact that the animals mounted a strong immune response is completely irrelevant. We KNOW they mounted a strong immune response. We also know they died some months later when a different strain of the virus emerged. Bottom line: The production of antibodies does not mean a drug is safe.

The obvious purpose of the trials was to get the vaccines over the finish-line before anyone figured out what was going on. It’s the same reason why the drug companies “unblinded” their human trials after the vaccines got the green light from the FDA. Shortly after the trials were concluded, the people in the placebo arm were allowed to get vaccinated.

Why would they do that? Why would they vaccinate the people who willingly allowed themselves to be guinea pigs for the sake of public health, only to vaccinate them shortly after, thus, eliminating any chance of finding out what the long-term safety issues might be? It makes no sense, does it?

Take a look at this short clip from the British Medical Journal whose scientists are equally bewildered:

“The (drug) companies say they have an ethical obligation to unblind volunteers so they can receive the vaccine. But some experts are concerned about a “disastrous” loss of critical information if volunteers on a trial’s placebo arm are unblinded

Although the FDA has granted the vaccines emergency use authorization, to get full license approval two years of follow-up data are needed. The data are now likely to be scanty and less reliable given that the trials are effectively being unblinded.

Consumer representative Sheldon Toubman, a lawyer and FDA advisory panel member, said that Pfizer and BioNTech had not proved that their vaccine prevents severe covid-19. “The FDA says all we can do is suggest protection from severe covid disease; we need to know that it does that,” he said.

He countered claims, based on experience with other vaccines, six weeks of follow-up was long enough to detect safety signals. Six weeks may not be long enough for this entirely new type of “untested” [mRNA] vaccine, Toubman said.

Goodman wants all companies to be held to the same standard and says they should not be allowed to make up their own rules about unblinding. He told The BMJ that, while he was “very optimistic” about the vaccines, “blowing up the trials” by allowing unblinding “will set a de facto standard for all vaccine trials to come.” And that, he said, “is dangerous.”

(“Covid-19: Should vaccine trials be unblinded?” The British Medical Journal )

Do you like his choice of words: “blowing up the trials”? Do you think it is a fair description of what the drug companies did?

Yes, it is.

And what possible motive would the drug companies have to blow up the trials? I can see only two possibilities:

  1. They think their vaccine is so terrific, it will save the lives of many of the people in the placebo group.
  2. They expect a high percentage of the people in the vaccine group to get either severely sick or die, so they want to hide the evidence of vaccine-linked injury.

Which is it?

You know the answer. Everyone watching this farce knows the answer.

Question – Okay, so let’s cut to the chase: Are the vaccines are safe or not?

No, they are not safe. The way we decide whether a drug is safe or not is by putting it through a rigorous process of testing and clinical trials. After the testing, the data is passed on to physicians, statisticians, chemists, pharmacologists, and other scientists who review the data and make their recommendations or criticisms. That didn’t happen with the Covid vaccines, in fact, all the normal standards and protocols were suspended in the name of “urgency”. But many believe that the “urgency” was manufactured to push through vaccines that would never have been approved on their own merits. All you have to do is look through the vaccine injury data (VAERS) and you’ll see this is the most lethal medical intervention of all time and, yet, the public health experts, the media and the government keep crowing that they’re “safe and effective”. It’s nonsense and the drug companies know it’s nonsense which is why they reject all liability for the people that are going to be killed by these “poison-death shots.”

Do you know what goes on inside your body after you are injected with one of these “gene based” vaccines?

Once the vaccine enters the bloodstream it penetrates the cells that line the blood vessels forcing them to produce spike proteins that protrude into the bloodstream like millions of microscopic thorns. These thorns activate blood platelets which trigger blood clotting followed shortly after by an immune response that destroys the infected cells thus weakening the vascular system while draining the supply of killer lymphocytes. In this way, the vaccine launches a dual attack on the body’s critical infrastructure causing widespread tissue damage throughout the circulatory system while leaving the immune system less able to fend off future infection.

Now if you think you can have a long-and-happy without a functioning circulatory system, then none of this matters. But if you’re bright enough to realize that wreaking havoc on your vascular system is the fast-track to the graveyard, then you’ll probably understand that injecting these “poison-death shots” is a particularly bad idea.

By the way, it’s a real stretch to call these hybrid injections, “vaccines”. They have about as much in common with a traditional vaccine as a python does with a coffee table. Nothing. The “vaccine” moniker was chosen in order to shore-up public confidence, that’s all. It’s part of a marketing strategy. There is no real similarity. The majority of people trust vaccines and see them as a shining example of medical achievement. The drug companies wanted to tap into that trust and use it for their own purposes. That’s why they called it a “vaccine” instead of “gene therapy” which more accurately describes ‘what it does.’ But–like we said– it’s just a marketing strategy.

Have you ever wondered how the drug companies were able to roll out their own-individual vaccines just weeks apart from each other? That’s a pretty good trick, don’t you think; especially since vaccine development typically takes from 10 to 15 years. How do you think they managed that? Here’s an excerpt from an article which provides a little background on the topic:

“The virus behind the outbreak that began in Wuhan, China, was identified on Jan. 7. Less than a week later — on Jan. 13 — researchers at Moderna and the NIH had a proposed sequence for an mRNA vaccine against it, and, as the company wrote in government documents, “we mobilized toward clinical manufacture.” By Feb. 24, the team was shipping vials from a plant in Norwood, Mass., to the National Institute of Allergy and Infectious Diseases, in Bethesda, Md., for a planned clinical trial to test its safety.” (“Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals”, Stat )

Got that? “The virus broke out in Wuhan… on Jan. 7, and less than a week later Moderna had a proposed sequence for an mRNA vaccine against it???

Really? Is that the same Moderna that had been playing-around with mRNA for over a decade but was never able to successfully bring a vaccine to market?

Yep, the very same company. Here’s more:

“And by Feb. 24, the team was shipping vials from a plant in Norwood, Mass??”

Wow! Another Covid miracle! You almost get whiplash watching these companies crank out their “wonder drugs” at record-breaking speed.

Keep in mind, there’s a very high probability that the virus was man-made, (In other words, it’s a bioweapon.) and the people who have been implicated in the funding and creation of that bioweapon are also closely aligned with the big drug companies that have produced the antidote in record time that has already netted tens of billions of dollars in profits for a drug for which there was no reliable animal testing, no long-term safety data, and no formal regulatory approval.

So I’ll ask you again: Doesn’t that all sound a bit suspicious?

Is it really that hard to see the outline of a political agenda here? After all, aren’t the drug companies working with the regulatory agencies that are working with the public health officials that are working with the media that are working with the corrupted politicians that are working with the Intel agencies that are working with the meddling globalist billionaires that are working with the giant private equity firms that oversee the entire operation pulling the appropriate strings whenever needed?

It sure looks like it.

And, don’t the tectonic social changes we’ve seen in the last year have more to do with a broader scorched-earth campaign launched by the “parasite class” against the rest of humanity than they do with a fairly-mild virus that kills mainly old and frail people with multiple underlying health conditions?

Right, again. In fact, many have noticed the cracks in the pandemic artifice from the very beginning, just as many have pointed out that the virus-meme is just the mask behind which parasites continue to conduct their global restructuring project. In short, it’s all about politics; bare-knuckle, take-no-prisoners NWO politics.

Answer – You’ve asked a number of questions about the animal trials, but none about the biodistribution and the pharmacokinetics studies that were done at the same time. Why is that? (Note--Pharmacokinetics; “the branch of pharmacology concerned with the movement of drugs within the body.”)

Question– I didn’t know there were any. Did the media report on them?

Answer – No, they didn’t. They completely ignored them, even though they were produced by Pfizer and provide essential information about where the substance in the vaccine goes in the body, in what amounts, and for how long. By knowing how the drug is distributed, it is possible to make educated assumptions about its effect on the organs and other tissue. In other words, these studies are invaluable. The Doctors for Covid Ethics have done extensive research on the studies and written a report titled “The Pfizer mRNA vaccine: pharmacokinetics and toxicity”. Here’s a few excerpts that help to illustrate the dangers of the vaccines:

“As with any drug, a key consideration for the toxicity of the COVID mRNA vaccines is where exactly in the body they end up, and for how long they will stay there. Such questions, which are the subject of pharmacokinetics, are usually thoroughly investigated during drug development. Initial studies on pharmacokinetics and also on toxicity are carried out in animals… this document has rather far-reaching implications: it shows that Pfizer—as well as the authorities that were apprised of these data— must have recognized the grave risks of adverse events after vaccination even before the onset of clinical trials. Nevertheless, Pfizer’s own clinical trials failed to monitor any of the clinical risks that were clearly evident from these data, and the regulatory authorities failed to enforce proper standards of oversight. This dual failure has caused the most grievous harm to the public….

What do Pfizer’s animal data presage for biological effects in humans?

  • Rapid appearance of spike protein in the circulation.
  • Toxicity to organs with expected high rates of uptake, in particular placenta and
    lactating breast glands
  • Penetration of some organs might be higher with the real vaccine than with this
    luciferase model… The rapid entry of the model vaccine into the circulation means that we must expect the spike protein to be expressed within the circulation, particularly by endothelial cells. ( Endothelial – The thin layer of cells lining the blood vessels) We have seen before that this will lead to activation of blood clotting through direct activation of platelets and also, probably more importantly, through immune attack on the endothelial cells…

Summary

Pfizer’s animal data clearly presaged the following risks and dangers:

  • blood clotting shortly after vaccination, potentially leading to heart attacks, stroke, and venous thrombosis
  • grave harm to female fertility
  • grave harm to breastfed infants
  • cumulative toxicity after multiple injections

With the exception of female fertility, which can simply not be evaluated within the short period of time for which the vaccines have been in use, all of the above risks have been substantiated since the vaccines have been rolled out—all are manifest in the reports to the various adverse event registries. Those registries also contain a very considerable number of reports on abortions and stillbirths shortly after vaccination, which should have prompted urgent investigation. […]

Of particularly grave concern is the very slow elimination of the toxic cationic lipids. In persons repeatedly injected with mRNA vaccines containing these lipids… this would result in cumulative toxicity. There is a real possibility that cationic lipids will accumulate in the ovaries. The implied grave risk to female fertility demands the most urgent attention of the public and of the health authorities.

Since the so-called clinical trials were carried out with such negligence, the real trials are occurring only now—on a massive scale, and with devastating results. … Calling off this failed experiment is long overdue. Continuing or even mandating the use of this poisonous vaccine, and the apparently imminent issuance of full approval for it are crimes against humanity.” (“The Pfizer mRNA vaccine: pharmacokinetics and toxicity”, Doctors for Covid Ethics )

Don’t you think people are entitled to know what the government wants to inject into their bodies? Don’t you think they have a right to know how it will effect their immune systems, their vital organs and their overall health? Don’t you think they have the right to decide for themselves which drugs they will take and which they will refuse to take?

Forcing someone to take a drug he does not want, is not just wrong. It’s un-American. Which is why people should reject vaccine mandates as a matter of principle. They are an attack on personal liberty, the foundation of our constitutional system. It’s a principle worth dying for.

As for the mass vaccination campaign, it is the most maniacally-genocidal project ever concocted by man. There’s simply no way to calculate the amount of suffering and death we are about to face for trusting people whose policies were obviously shaped by their undiluted hatred of humanity. As German microbiologist Dr. Sucharit Bhakdi said:

“In the end, we’re going to see mass illness and deaths among people who normally would have had wonderful lives ahead of them.”

It is a great tragedy.

October 18, 2021 Posted by | Civil Liberties, Deception, Science and Pseudo-Science, Timeless or most popular, War Crimes | , , | 3 Comments

FDA Fast-Tracks RSV mRNA ‘Vaccine’

By Dr. Joseph Mercola | September 3, 2021

Respiratory syncytial virus (RSV) — a respiratory virus that causes typically mild cold-like symptoms — has apparently been selected as the next invisible boogey man. Most children have been exposed to RSV by their second birthday.

The fact that most children survive past the age of 2 tells you something about the risks involved. That said, in very rare cases, RSV can progress to pneumonia or bronchiolitis (inflammation of the small airways of the lungs).

RSV Emerges Out of Season Around the World

According to reports, RSV is now raging around the world, from New Zealand1 to Japan2 and the U.S.,3 where it hit so hard in June 2021 that the Centers for Disease Control and Prevention issued an emergency alert4 for parts of the southern United States.

The CDC encouraged testing for RSV among patients who tested negative for COVID-19 but had “acute respiratory illness” symptoms. They also advised health care personnel, child care providers and staff of long-term care facilities to stay home from work if they had respiratory symptoms, even if they test negative for COVID, as they might have RSV.

In New Zealand, health officials said there were few cases of RSV in 2020 during the pandemic and, while it’s normally a winter disease, it’s now making a comeback off-season in 2021. According to Stuff.co.nz,5 the outbreak “was more than twofold greater than the historical average from 2014 to 2019 for this time of year.”

Similar reports have been published in Japan where, in early July 2021, the National Institute of Infectious Diseases warned of RSV infections outside the normal peak period. According to the Japan Times :6

“… the number of RSV patients per medical institution was 3.87 in the week ending June 27 — the highest number of cases since 2019. In 2018, the year the counting system was changed, the infection count peaked in September at 2.46, and it reached 3.45 patients per medical institution a year later.”

August 3, 2021, U.S. health officials reported that RSV had started to taper off by midsummer, but a resurgence is now seen, with a “record-breaking 563 new RSV cases” reported in the week before August 3.7

FDA Fast-Tracks mRNA Shot Against RSV

That same day, August 3, 2021, the Food and Drug Administration granted fast-track designation to Moderna for an mRNA-based injection against this common cold virus. As reported in a Moderna press release:8

“… the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for mRNA-1345, its investigational single-dose mRNA vaccine against respiratory syncytial virus (RSV) in adults older than 60 years of age.

‘We are pursuing an mRNA RSV vaccine to protect the most vulnerable populations — young children and older adults,’ said Stéphane Bancel, Chief Executive Officer of Moderna.

‘We are studying mRNA-1345 in these populations in an ongoing clinical trial and we look forward to sharing data when available … We have accelerated research and development of our infectious disease therapeutic area and we will continue to advance our mRNA vaccines into new areas of high unmet need.'”

Moderna’s press release correctly points out that there’s no approved vaccine available for RSV. What they don’t mention is why. The reason there’s no RSV vaccine on the market is the same reason why there has never been a coronavirus vaccine, and that is because none of them were able to pass trials.

As with coronavirus, previous efforts to develop an RSV vaccine have met with failure as test subjects have a pesky tendency to die or become seriously ill when exposed to the wild virus, thanks to paradoxical immune enhancement (PIE), also known as antibody dependent enhancement (ADE).9

RSV Shot Builds on COVID Jab

Moderna’s RSV shot uses the same lipid nanoparticle as its COVID-19 injection. The primary difference between the two shots is the coding of the mRNA. In the RSV shot, the mRNA encodes for a prefusion F glycoprotein.

Prefusion F protein is a protein that mediates the RSV virus’ entry into your cells and is known to elicit a neutralizing antibody response.10 Under normal circumstances, it’s hard to imagine an RSV vaccine built on a novel mRNA platform getting fast-tracked, but we’re no longer in normal times.

The rollout of mRNA COVID shots have, as predicted, paved the way for any number of new mRNA-based injections going straight to human trials. So, should you ever feel like your body lacks in synthetic mRNA, fear not. This is just the beginning. Those who embrace vaccine passports will surely find themselves called to the nearest vaccine center several times a year for mandatory refills.

Are We Creating a Public Health Disaster?

The decision to fast-track yet another mRNA injection fails to take into consideration the possibility that we might already be creating an avalanche of ADE-related illness from the COVID shot. Adding another injection for a respiratory virus that has historically been associated with ADE could be extremely risky.

As noted in a September 9, 2020, Nature Microbiology paper titled “Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies”:11

“Data from the study of SARS-CoV and other respiratory viruses suggest that anti-SARS-CoV-2 antibodies could exacerbate COVID-19 through antibody-dependent enhancement (ADE). Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical safety risks related to ADE, resulting in failed vaccine trials …

ADE can increase the severity of multiple viral infections, including other respiratory viruses such as respiratory syncytial virus (RSV) and measles.

ADE in respiratory infections is included in a broader category named enhanced respiratory disease (ERD), which also includes non-antibody-based mechanisms such as cytokine cascades and cell-mediated immunopathology …

Furthermore, ADE and ERD has been reported for SARS-CoV and MERS-CoV both in vitro and in vivo … ADE pathways can occur when non-neutralizing antibodies or antibodies at sub-neutralizing levels bind to viral antigens without blocking or clearing infection …

ADE has been observed in SARS, MERS and other human respiratory virus infections including RSV and measles, which suggests a real risk of ADE for SARS-CoV-2 vaccines and antibody-based interventions …

Going forwards, it will be crucial to evaluate animal and clinical datasets for signs of ADE, and to balance ADE-related safety risks against intervention efficacy if clinical ADE is observed.”

In case you missed it, the authors specifically point out that ADE can worsen the severity of RSV. Theoretically then, if you get the COVID shot and end up with ADE, then contracting RSV could turn into a far more serious problem than it would otherwise.

Have COVID Policies Weakened Immune Systems?

While the COVID shot could play a role if we start seeing severe RSV in adults, it’s unlikely to be part of the equation when it comes to children, as the shot is still not authorized for children under the age of 12. More than likely, the out-of-season rise in RSV among children is related to the easing of restrictions after not being exposed to normal pathogens for extended periods of time.

During the past 18 months, as most of the world has been masked up, locked down and otherwise distanced from one another, children and adults have not been exposed to viruses and bacteria as they normally would.

On the one hand, there has been a significant reduction in the number of people reporting colds, flu and other infectious diseases. On the other hand, some health experts are questioning if this lack of exposure may have increased the risk for some to experience more illnesses as children reenter school and adults reenter the workforce.12

The two main parts of your immune system are your innate immune system, which you were born with, and your adaptive immune system, which is developed as you’re exposed to pathogens.13 A healthy immune system keeps a record of every pathogen to which it has been exposed so that it can quickly recognize it if exposed again. Your immune system is activated when you’re exposed to a protein it doesn’t recognize, called an antigen.

Since the system is so complex, there are several potential ways in which things can go wrong. If your immune system doesn’t work correctly it can result in immunodeficiency diseases, resulting in more and longer-lasting sickness.

Some health experts are concerned that children may have experienced greater harm to their immune system than adults since they have spent the better part of the last 18 months isolated from nearly every exposure.14

From what researchers are now finding, it is infants and children who may have the most detrimental response to social distancing.15 Since the beginning of 2020, doctors and hospitals have noticed a significant reduction in the number of bacterial and viral infections children have been contracting. This includes bronchiolitis, measles, varicella, RSV and pertussis.

A paper16 published in August 2021, from the Pediatric Infectious Disease Group postulated nonpharmaceutical interventions imposed during 2020 could result in larger epidemics of infectious diseases once these interventions are lifted.

Rising Number of Infants With RSV Related to Immunity Debt

Some experts are calling a rising number of RSV infections in babies a “debt of immunity” created because infants born during 2020 had a lack of exposure to normal pathogens.17 Once infants and children are introduced to these environmental pathogens en masse, it can instigate a precipitous rise in cases.

According to The Guardian,18 New Zealand reported a 99.9% reduction in flu and 98% reduction in RSV during 2020. This nearly eliminated the spike of deaths that happens during the winter months from flu and RSV. In the short-term, it may have prevented an overload of the health care system while others were being treated for COVID-19.

However, in the long run, it may have created an additional problem in infants and children. When the immune system is not challenged at an early age, it can lead to larger outbreaks, which again taxes the health care system. As of early July 2021, New Zealand had reported nearly 1,000 cases of RSV over five weeks. The usual number reported is 1,743 over 29 weeks.

Doctors are hoping this doesn’t necessarily mean there will be more RSV cases, only that they are occurring in more rapid succession early in the season. The current outbreak has stretched the resources in New Zealand and Australia, which is also experiencing a surge in cases. New Zealand’s director general of health Dr. Ashley Bloomfield commented to a reporter from The Guardian saying he was:19

“… certainly concerned about the sharp surge in RSV cases … There’s some speculation that [the current outbreak] may be partly exacerbated by the fact we didn’t have any last year and so there is a bigger pool of children who are susceptible to it.”

In Canada, Wellington-based epidemiologist Michael Baker warns that his country may also see a similar trend in cases of RSV in the next year, warning that babies who were born prematurely are most at risk.20

That said, while Canada may see a rebound in RSV infections, Baker does not think that a lack of exposure to pathogens at an early age will have “in any way impeded the development of a healthy immune system.”

Is a Fast-Tracked RSV Shot the Answer?

Considering the multitude of problems associated with the gene-based COVID shots, I’m not optimistic about the development of a fast-tracked mRNA “vaccine” against RSV. The risks are numerous. Already, we’re seeing trends that could signal that ADE is at play in older people who got the jab (but not younger people).

In the U.K., as of August 15, 2021, 68% of COVID patients admitted to hospital who were over the age of 50 had received one or two COVID injections. Mortality statistics reveal the exact same trend. In the over-50 group, 70% of COVID deaths were either partially or fully “vaccinated.”21

Could this be because older people are developing ADE and therefore suffer more serious infection when exposed to the SARS-CoV-2 virus? In the under-50 category, the unvaccinated make up a majority of hospitalizations and deaths in the U.K., so perhaps the shot affects different age groups differently.

Older people are also the target group of the RSV shot, and infants and young children are a target for both COVID shots and RSV shots. Time will tell what the ramifications of programming the bodies of the very young and the very old to produce more than one antigen might be. But my guess is it won’t be good.

Sources and References

September 3, 2021 Posted by | Science and Pseudo-Science, Timeless or most popular | , , | Leave a comment

Dozens of people develop rare blood disorder after taking coronavirus vaccines – reports

RT | February 10, 2021

At least 36 recipients of Pfizer’s and Moderna’s Covid-19 vaccines in the US have developed a rare immune disorder that attacks the blood, according to reports. One patient is dead, and doctors can’t rule out blaming the vaccine.

Dr. Gregory Michael – a 56-year-old obstetrician-gynecologist who ran his own practice at Miami Beach’s Mount Sinai Medical Center for more than a decade – died in January of a brain hemorrhage. He had received a dose of the Pfizer-BioNTech coronavirus vaccine two weeks earlier, and immediately developed immune thrombocytopenia, a rare and sometimes fatal blood disorder.

Michael is one of at least 36 people to have developed the condition after receiving either Pfizer’s or Moderna’s coronavirus vaccines, according to a New York Times report published on Monday. The cases were self-reported to the government’s Vaccine Adverse Event Reporting System (VAERS) before the end of January, meaning more people could have developed the condition since then.

Immune thrombocytopenia is a rare condition affecting an estimated 50,000 people in the US. The condition is caused by the body’s own immune system attacking the platelets that are the component of the blood responsible for clotting. With their blood unable to clot, patients often develop internal or external bruising, which may look like a rash. In several cases like Michael’s, the condition has caused massive hemorrhages or strokes.

One patient contacted by the Times suffered heavy vaginal bleeding two weeks after receiving Moderna’s vaccine and required platelet transfusions and steroid treatment to survive. Another woman was hospitalized with bruising and bleeding blisters in her mouth just a day after receiving the same shot. Her condition deteriorated to the point where doctors concerned that a slight knock would trigger fatal bleeding were afraid to move her from the hospital bed.

The cases can’t all conclusively be linked with the vaccines, but Dr. James Bussel, a hematologist and expert on the condition, told the Times that an association “is possible.”

“Having it happen after a vaccine is well-known and has been seen with many other vaccines,” he said. “Why it happens, we don’t know.”

Unlike traditional vaccines, which use an inactive form of the pathogen they protect against, both Pfizer’s and Moderna’s offerings are mRNA vaccines. Technologically new and therefore untested on a mass basis, these vaccines work by introducing into the body’s cells a strand of RNA with instructions that tell the person’s DNA how to begin making antibodies.

Researchers at Cambridge University state that side effects could include “autoimmune reactions,” but Harvard scientists say that mRNA vaccines produce “a stronger type of immunity” than their traditional counterparts.

Immune thrombocytopenia can also develop as a result of certain medications and cancers, from influenza, and seemingly from Covid-19 itself. As early as last spring, long before any vaccines were near completion, doctors in the US, Europe, India and China noticed the condition in Covid patients and suspected a link.

Officials with the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said that they are investigating the VAERS reports, while both Pfizer and Moderna told the Times that they are monitoring the safety of their vaccines.

Doctors contacted by the Times still insist that vaccination is safe, and that the risk of developing serious illness from the coronavirus is still higher than the risk of side effects from the vaccine.

February 10, 2021 Posted by | Aletho News | , , | 1 Comment

COVID-19: RDIF Points to Absence of Long-Term Studies on Vaccines Based on Monkey Adenoviral Vectors

By Aleksandra Serebriakova – Sputnik – 09.09.2020

The third round of trials for the AstraZeneca anti-COVID-19 drug is now on pause over “potentially unexplained illness” in a participant in the UK. On 11 August, Russia registered its own Sputnik V anti-coronavirus vaccine, which is said to have been developed in a different way.

The Russian Direct Investment Fund (RDIF) the investor which has funded the development of Russia’s Sputnik V anti-coronavirus vaccine, could not comment on the halt of AstraZeneca trials, it said in a statement.

However, RDIF pointed out that the fund’s CEO Kirill Dmitriev had previously discussed the differences between the human adenoviral vector-based platform used in Russia’s Sputnik V vaccine and those used by some of their international colleagues, that rely on “novel unproven technologies such as monkey adenoviral vectors or mRNA”.

“The safety of the human adenoviral vector used in Sputnik V has been proven over decades in over 250 clinical studies, as human adenovirus has been shown to be the safest vaccine delivery mechanism and the most ‘organic for humans’, as human adenovirus has coexisted with humans for over 100,000 years,” RFID said.

Meanwhile, “mRNA and monkey adenoviral vector-based platforms have not been studied over a long period of time,” RDIF CEO Dmitriev pointed out this Tuesday.

Commenting on the so-called “pledge of safety” earlier voiced by the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi in relation to the development of the first COVID-19 vaccines, Dmitriev stressed that this plea was “insufficient” as it did not “discuss the lack of long-term studies on the carcinogenic effects and impact on fertility of newly-developed vaccine technologies”.

“Since some of the companies developing these vaccines have taken the ‘pledge of safety’, we would like to stress that public health and safety requires not only short-term evidence of a lack of serious adverse effects, but also the safety and efficacy proved by the results of long-term studies,” Dmitriev added.

AstraZeneca COVID-19 Vaccine Trials on Pause

It was revealed this week that the third round of trials for the AstraZeneca anti-COVID-19 vaccine has been halted due to a “potentially unexplained illness” which had developed in a participant in the United Kingdom, without further specifications about the nature of possible side effects. The vaccine in question was developed in partnership with Oxford University and has reportedly involved around 30,000 participants in the UK, US, Brazil and South Africa. AstraZeneca described the pause as “routine” so as to allow for a “standard review process” of “safety data”.

Russia’s First Anti-Coronavirus Vaccine

On 11 August, Russia registered the world’s first vaccine against COVID-19, called Sputnik V, which was developed by the Gamaleya National Research Centre of Epidemiology and Microbiology and the RDIF after several rounds of clinical trials. On Monday, the vaccine was made available to the public.

According to RDIF, Russia has now received requests for 1 billion doses of the vaccine; at least 20 countries, including the UAE, Saudi Arabia, Indonesia, Philippines, Mexico, Brazil and India, have expressed an interest in obtaining Sputnik V.

September 9, 2020 Posted by | Aletho News | , , , , , , , , , | Leave a comment

Coronavirus Gives a Dangerous Boost to DARPA’s Darkest Agenda

By Whitney Webb | The Last American Vagabond | May 4, 2020

In January, well before the coronavirus (Covid-19) crisis would result in lockdowns, quarantines and economic devastation in the United States and beyond, the U.S. intelligence community and the Pentagon were working with the National Security Council to create still-classified plans to respond to an imminent pandemic. It has since been alleged that the intelligence and military intelligence communities knew about a likely pandemic in the United States as early as last November, and potentially even before then.

Given this foreknowledge and the numerous simulations conducted in the United States last year regarding global viral pandemic outbreaks, at least six of varying scope and size, it has often been asked – Why did the government not act or prepare if an imminent global pandemic and the shortcomings of any response to such an event were known? Though the answer to this question has frequently been written off as mere “incompetence” in mainstream media circles, it is worth entertaining the possibility that a crisis was allowed to unfold.

Why would the intelligence community or another faction of the U.S. government knowingly allow a crisis such as this to occur? The answer is clear if one looks at history, as times of crisis have often been used by the U.S. government to implement policies that would normally be rejected by the American public, ranging from censorship of the press to mass surveillance networks. Though the government response to the September 11 attacks, like the Patriot Act, may be the most accessible example to many Americans, U.S. government efforts to limit the flow of “dangerous” journalism and surveil the population go back to as early as the First World War. Many of these policies, whether the Patriot Act after 9/11 or WWI-era civilian “spy” networks, did little if anything to protect the homeland, but instead led to increased surveillance and control that persisted long after the crisis that spurred them had ended.

Using this history as a lens, it is possible to look at the current coronavirus crisis to see how the long-standing agendas of ever-expanding mass surveillance and media censorship are again getting a dramatic boost thanks to the chaos unleashed by the coronavirus pandemic. Yet, this crisis is unique because it also has given a boost to a newer yet complimentary agenda that — if fulfilled – would render most, if not all, other government efforts at controlling and subduing their populations obsolete.

DARPA Dystopia

For years, the Pentagon’s Defense Advanced Research Projects Agency (DARPA) has remained largely out of sight and out of mind for most Americans, as their research projects are rarely covered by the mainstream media and, when they are, their projects are often praised asbringing science fiction movies to life.” However, there have been recent events that have marred DARPA’s often positive portrayal by media outlets, which paint the agency as a beacon of scientific “progress” that has “changed the world” for the better.

For instance, in 2018, a group of European scientists accused the DARPA’s “Insect Allies” program of actually being a dystopian bioweapons program that would see insects introduce genetically modified viruses into plants to attack and devastate a targeted nation’s food supply. DARPA, of course, maintained that its intent to use these insects to genetically modify plants was instead about “protecting” the food supply. Regardless of DARPA’s assertions that it is merely a “defensive” program, it should be clear to readers that such a technology could easily be used either way, depending on the wielder.

Though DARPA’s futuristic weapons of war often get the most attention from media, the agency has long standing interests in tinkering with, not just the biology of plants, but of humans. DARPA, which is funded to the tune of approximately $3 billion a year, has various avenues through which it pursues these ambitions, with many of those now under the purview of the agency’s “Biological Technologies Office” (BTO), created in 2014. As of late, some of DARPA’s human biology and biotech projects at its BTO have been getting a massive PR boost thanks to the current coronavirus crisis, with recent reports even claiming that the agency “might have created the best hopes for stopping Covid-19.”

Most of these technologies garnering positive media coverage thanks to Covid-19 were developed several years ago. They include the DARPA-funded platforms used to produce DNA and RNA vaccines, classes of vaccine that have never been approved for human use in the U.S. and involve injecting foreign genetic material into the human body. Notably, it is this very class of vaccine, now being produced by DARPA-partnered companies, that billionaire and global health “philanthropist” Bill Gates recently asserted has him “most excited” relative to other Covid-19 vaccine candidates. Yet, key aspects regarding these vaccines and other DARPA “healthcare” initiatives have been left out of these recent positive reports, likely because they provide a window into what is arguably the agency’s darkest agenda.

“In Vivo Nanoplatforms”

In 2006, DARPA announced its Predicting Health and Disease (PHD) program, which sought to determine “whether an individual will develop an infectious disease prior to the onset of symptoms.” The PHD program planned to accomplish this by “identifying changes in the baseline state of human health through frequent surveillance” with a specific focus on “viral, upper respiratory pathogens.”

Three years later, in 2010, DARPA-funded researchers at Duke University created the foundation for this tool, which would use the genetic analysis of blood samples to determine if someone is infected with a virus before they show symptoms. Reports at the time claimed that these “preemptive diagnoses” would be transmitted to “a national, web-based influenza map” available via smartphone.

Following the creation of DARPA’s BTO in 2014, this particular program gave rise to the “In Vivo Nanoplatforms (IVN)” program. The diagnostics branch of that program, abbreviated as IVN:Dx, “investigates technologies that incorporate implantable nanoplatforms composed of bio-compatible, nontoxic materials; in vivo sensing of small and large molecules of biological interest; multiplexed detection of analytes at clinically relevant concentrations; and external interrogation of the nanoplatforms without using implanted electronics for communication.” Past reports on the program describe it as developing “classes of nanoparticles to sense and treat illness, disease, and infection on the inside. The tech involves implantable nanoparticles which sense specific molecules of biological interest.”

DARPA’s IVN program has since helped to finance and produce “soft, flexible hydrogels that are injected just beneath the skin to perform [health] monitoring and that sync to a smartphone app to give the use immediate health insights,” a product currently marketed and created by the DARPA-funded and National Institutes of Health (NIH)-funded company Profusa. Profusa, which has received millions upon millions from DARPA in recent years, asserts that the information generated by their injectable biosensor would be “securely shared” and accessible to “individuals, physicians and public health practitioners.” However, the current push for a national “contact tracing” system based on citizens’ private health data is likely to expand that data sharing, conveniently fitting with DARPA’s years-old goal of creating a national, web-based database of preemptive diagnoses.

Profusa is also backed by Google, which is intimately involved in these new mass surveillance “contact tracing” initiatives, and counts former Senate majority leader William Frist among its board members. They are also partnered with the National Institutes of Health (NIH). The company also has considerable overlap with the diagnostic company Cepheid, which recently won FDA approval for its rapid coronavirus test and was previously awarded lucrative government contracts to detect anthrax in the U.S. postal system. As of this past March, Profusa again won DARPA funding to determine if their injectable biosensors can predict future pandemics, including the now widely predicted “second wave” of Covid-19, and detect those infected up to three weeks before they would otherwise show symptoms. The company expects to have its biosensors FDA licensed for this purpose by early next year, about the same time a coronavirus vaccine is expected to be available to the general public.

“Living Foundries”

Another long-standing DARPA program, now overseen by BTO, is known as “Living Foundries.” According to DARPA’s website, Living Foundries “aims to enable adaptable, scalable, and on-demand production of [synthetic] molecules by programming the fundamental metabolic processes of biological systems to generate a vast number of complex molecules that are not otherwise accessible. Through Living Foundries, DARPA is transforming synthetic biomanufacturing into a predictable engineering practice supportive of a broad range of national security objectives.”

The types of research this “Living Foundries” program supports involves the creation of “artificial life” including the creation of artificial genetic material, including artificial chromosomes, the creation of “entirely new organisms,” and using artificial genetic material to “add new capacities” to human beings (i.e. genetically modifying humans through the insertion of synthetically-created genetic material).

The latter is of particular concern (though all are honestly concerning), as DARPA also has a project called “Advanced Tools for Mammalian Genome Engineering,” which – despite having “mammalian” in the name – is focused specifically on improving “the utility of Human Artificial Chromosomes (HACs),” which DARPA describes as a “fundamental tool in the development of advanced therapeutics, vaccines, and cellular diagnostics.” Though research papers often focus on HACs as a revolutionary medical advancement, they are also frequently promoted as a means of “enhancing” humans by imbuing them with non-natural characteristics, including halting aging or improving cognition.

DARPA is known to be involved in research where these methods are used to create “super soldiers” that no longer require sleep or regular meals, among other augmented “features,” and has another program about creating “metabolically dominant” fighters. Reports on these programs also discuss the other, very disconcerting use of these same technologies, “genetic weapons” that would “subvert DNA” and “undermine people’s minds and bodies.”

Another potential application being actively investigated by DARPA is its BioDesign program, which is examining the creation of synthetic organisms that are created to be immortal and programmed with a “kill switch” allowing a synthetic, yet organic organism to be “turned off” at any time. This has led some to speculate such research could open the doors to the creation of “human replicants” used for fighting wars and other tasks, such as those that appear in the science fiction film Bladerunner.

However, these genetic “kill switches” could also be inserted into actual humans through artificial chromosomes, which – just as they have the potential to extend life – also have the potential to cut it short. Notably, it was revealed in 2017 that DARPA had invested $100 million in “gene drive” research, which is involves the use of genetic modification to wipe out entire populations, explaining why it it often referred to as a “genetic extinction” technology.

In addition, other DARPA experiments involve the use of genetically modified viruses that insert genetic material into human cells, specifically neurons in the brain, in order to “tweak” human brain chemistry. In one example, DARPA-funded research has altered human brain cells to produce two new proteins, the first allowing neural activity to be easily detected by external devices and the second allowing “magnetic nanoparticles” to “induce an image or sound in the patient’s mind.”

“Next-Generation Nonsurgical Neurotechnology”

Changing human brain chemistry and functionality at the cellular level is only one of numerous DARPA initiatives aimed at changing how human beings think and perceive reality. Since 2002, DARPA has acknowledged its efforts to create a “Brain-Machine Interface (BMI).” Though first aimed at creating “a wireless brain modem for a freely moving rat,” which would allow the animal’s movements to be remotely controlled, DARPA wasn’t shy about the eventual goal of applying such brain “enhancement” to humans in order to enable soldiers to “communicate by thought alone” or remotely control human beings (on the enemy side only, so they say) for the purposes of war.

The project, which has advanced greatly in recent years, has long raised major concerns among prominent defense scientists, some of whom warned in a 2008 report that “remote guidance or control of a human being” could quickly backfire were an adversary to gain access to the implanted technology (opening up the possibility of “hacking” a person’s brain), and they also raised concerns about the general ethical perils of such technologies. Work began in 2011 on developing “brain implants” for use in human soldiers, officially with the goal of treating neurological damage in veterans, and such implants have been tested on human volunteers in DARPA-funded experiments since at least 2015.

Concerns, like those raised by those defense scientists in 2008, have been regularly dismissed by DARPA, which has consistently claimed that its controversial research projects are tempered by their in-house “ethical experts.” However, it worth noting how DARPA’s leadership views these ethical conundrums, since they ultimately have the last word. For example, in 2015, Michael Goldblatt, then-director of DARPA’s Defense Sciences Office (DSO), which oversees most aspects of the agency’s “super soldier” program, told journalist Annie Jacobsen that he saw no difference between “having a chip in your brain that could help control your thoughts” and “a cochlear implant that helps the deaf hear.” When pressed about the unintended consequences of such technology, Goldblatt stated that “there are unintended consequences for everything.”

Thus, it is worth pointing out that, while DARPA-developed technologies – from human genetic engineering to the brain-machine interfaces – are often first promoted as something that will revolutionize and improve human health, DARPA sees the use of these technologies for such ends as being on the same footing as other dystopian and frankly nightmarish applications, like thought control. BMIs are no exception, having first been promoted as a way to “boost bodily functions of veterans with neural damage or post-traumatic stress disorder” and to allow amputees to control advanced prosthetics. While these do indeed represent major medical advances, DARPA’s leadership has made it clear that they see no distinction between the medical use of BMIs and using them to exert near total control over a human being by “guiding” their thoughts and even their movements.

Such stark admission from DARPA’s leadership makes it worth exploring the state of these current “brain-machine” interface programs as well as their explicit goals. For instance, one of the goals of DARPA’s Next-Generation Nonsurgical Neurotechnology (N3) program involves using “noninvasive or minimally invasive brain-computer interfaces” to “read and write” directly onto the brain.

According to one recent report on DARPA’s N3 program, one example of “minimally invasive” technologies would involve:

an injection of a virus carrying light-sensitive sensors, or other chemical, biotech, or self-assembled nanobots that can reach individual neurons and control their activity independently without damaging sensitive tissue. The proposed use for these technologies isn’t yet well-specified, but as animal experiments have shown, controlling the activity of single neurons at multiple points is sufficient to program artificial memories of fear, desire, and experiences directly into the brain.”

Though the purported goal of N3 is related to creating “thought-controlled” weapons that react and fire based on a soldier’s thoughts, the fact that the technology is also bidirectional, opens up the disturbing possibility that efforts will be made to control and program a soldier’s thoughts and perceptions as opposed to the other way around. This may be more of the plan than DARPA has publicly let on, since official military documents have openly stated that the Pentagon’s ultimate goal is to essentially replace human fighters with “self-aware” interconnected robots “who” will both design and conduct operations against targets chosen by artificial-intelligence systems. This weapons system of the not-so-distant future seems to have little room for human beings, even those capable of “controlling” weapons with their minds, suggesting that futurist military planners see soldiers with BMIs as a “weapon” that would also become connected to this same AI-driven system. It is also worth pointing out that DARPA has been attempting to create an “artificial human brain” since 2013.

In addition, reports on DARPA’s BMI efforts have suggested that this bidirectional technology will be used to “cloud the perception of soldiers” by “distancing them from the emotional guilt of warfare,” a move that would set a dangerous precedent and one that would surely result in a marked jump in war crimes.

Of course, these are just the admitted, potential “military” applications of such technology. Once this technology moves from the military to the civilian sphere, as several DARPA inventions have in the past, their use for “remote guidance”, “thought control” and/or the programming of thoughts and experiences is more than likely to be misused by governments, corporations and other power-brokers in the U.S. and beyond for the purposes of control.

The entrance of BMIs into the civilian sphere isn’t very far away, as DARPA executives and researchers who have worked on the N3 and other DARPA-backed BMI programs have since been “scooped up” by Verily (a Google-GlaxoSmithKline partnership), Elon Musk’s Neuralink and Facebook’s Building 8 – all of which have been working to bring “neuro-modulation” devices and BMIs to market.

“Human Bio-reactors”, “Nanotherapeutics” and DARPA-funded gene vaccines

As detailed above, DARPA often frames the controversial technologies it develops as being developed to mainly advance medicine and healthcare. Aside from the technologies already discussed, it is important to note that DARPA has been very interested in healthcare, specifically vaccines, for sometime.

For instance, in 2010, DARPA began developing a class of vaccine that could “inoculate against unknown pathogens,” a component of its Accelerated Manufacture of Pharmaceuticals program. The vaccine would inject thousands of synthetic antibodies, such as those developed through DARPA’s “Living Foundries” program, into the human body. These synthetic antibodies or “synbodies” would then “create an immunity toolkit that can be combined in myriad ways to tackle virtually any pathogen.”

That same year, DARPA began funding efforts to create “multiagent synthetic DNA vaccines” that would be delivered into the human body via “noninvasive electroporation” and was quickly promoted in media reports as a way to quickly produce vaccines compared to traditional vaccine production methods. This category of vaccine would involve the same type of synthetic DNA that DARPA was also simultaneously researching for the purposes of both “enhancing” and “subverting” human beings at the genetic level. It was also this year, 2010, that the Bill and Melinda Gates Foundation also began heavily funding DNA and RNA vaccines.

DNA vaccines, which were first created in 2005, have never been approved for human use in the United States and past studies have warned that they “possess significant unpredictability and a number of inherent harmful potential hazards” and that “there is inadequate knowledge to define either the probability of unintended events or the consequences of genetic modifications.” Another long-standing issue with such vaccines is mitigating “unwanted immune reactions” that result from natural immune response to the foreign genetic material they contain.

In 2011, DARPA announced its “Rapidly Adaptable Nanotherapeutics” program, which seeks to create a “platform capable of rapidly synthesizing therapeutic nanoparticles” aimed at combatting “evolving and even genetically engineered bioweapons.” DARPA’s plan for these nanoparticles, which media reports described merely as “tiny, autonomous drug delivery systems,” was to combine them with “small interfering RNA (siRNA),” which are snippets of RNA that can target and shut down specific genes. As Wired wrote at the time: “siRNA could be reprogrammed ‘on-the-fly’ and applied to different pathogens,” allowing nanoparticles to “be loaded up with the right siRNA molecules and sent directly to cells responsible for the infection.”

The creation of this program was shortly followed by DARPA’s decision in 2013 to fund Moderna Therapeutics to the tune of $25 million to develop their synthetic RNA vaccine production platform. DARPA funded the project to “develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons.”

Then, in 2015, DARPA’s research into vaccines involving synthetic antibodies and synthetic genetic material expanded, with them giving $45 million to the DNA vaccine company, Inovio Pharmaceuticals. This same year, DARPA-funded RNA and DNA vaccines began to be framed differently by both DARPA researchers and the media – who described the technology as transforming the human body into a “bio-reactor.”

In the years since, DARPA-backed DNA and RNA vaccine companies, including Moderna, Inovio as well as Germany’s CureVac, have been unable to get their products licensed for human use, largely due to the fact that their vaccines have failed to provide sufficient immunity in human trials. Examples of these ineffective vaccines include CureVac’s attempt at a rabies vaccine and Moderna’s efforts to create a vaccine for the Zika virus (which was funded by the U.S. government).

Several workarounds for this issue have been proposed, including vaccines where the genetic material (RNA or DNA) “self-amplifies.” However, the workaround of choice to this lack of immune response and other obstacles for DNA/RNA vaccines is the incorporation of nanotechnology into these vaccines. As a result, the use of nanoparticles as the carriers for the genetic material in these vaccines has been widely promoted and studied, as well as touted as the best way to improve their stability, increase their targeted delivery ability and enhance the immune response they provoke.

The combination of DNA or RNA vaccines with nanotechnology has already become reality thanks to the companies leading that field. For instance, the DARPA-backed DNA vaccine company Inovio Pharmaceuticals utilizes what reports refer to as “DNA nanotechnology” in their line of synthetic vaccines branded as “SynCon” by the company, which uses an undisclosed computer algorithm to design its vaccines. It is an interesting coincidence, then, that the Inovio “SynCon” vaccine for Covid-19 now appears to be ahead of the rest of the pack, with backing from Bill Gates, DARPA, the National Institute of Allergy and Infectious Diseases (NIAID) and other government agencies.

DARPA – Saving us from Covid-19?

In January, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would begin funding vaccine candidates for the coronavirus outbreak, long before it became a major global issue. CEPI describes itself as “a partnership of public, private, philanthropic and civil organizations that will finance and co-ordinate the development of vaccines against high priority public health threats” and was founded in 2017 by the governments of Norway and India along with the World Economic Forum (WEF) and the Bill and Melinda Gates Foundation. That month, CEPI only chose two pharmaceutical companies to receive funding for their efforts to develop a vaccine for Covid-19 – Moderna and Inovio Pharmaceuticals.

As previously mentioned, these two companies are DARPA-backed firms that frequently tout their “strategic alliance” with DARPA in press releases and on their websites. DARPA has also provided these companies with significant amounts of funding. For instance, the top funders behind Inovio Pharmaceuticals include both DARPA and the Pentagon’s Defense Threat Reduction Agency (DTRA) and the company has received millions in dollars in grants from DARPA, including a $45 million grant to develop a vaccine for Ebola. They were also recently awarded over $8 million from the U.S. military to develop a small, portable intradermal device for delivering DNA vaccines, which was jointly developed by Inovio and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), which also manages the “biodefense” lab at Fort Detrick.

In addition, the German company CureVac, which is also developing a CEPI-backed RNA vaccine for Covid-19, is another long-time recipient of DARPA funding. They were one of DARPA’s earliest investments in the technology, winning a $33.1 million DARPA contract to develop their “RNActive” vaccine platform in 2011.

In Moderna’s case, DARPA financed the production and development of their RNA vaccine production platform and their RNA therapy candidate for Chikungunya virus (their first for an infectious disease) was developed in direct collaboration with the agency. Since 2016, Moderna’s RNA vaccine program has received $100 million in funding from the Bill and Melinda Gates Foundation. The Gates Foundation has since poured millions directly into both Moderna’s and Inovio’s Covid-19 vaccine efforts.

Gates’ backing of DNA and RNA vaccines is significant, given that Gates – a billionaire with unparalleled influence and control over global healthcare policy – recently asserted that the best options for a Covid-19 vaccine are these same vaccines, despite the fact that they have never before been approved for use in humans. Yet, thanks to the emergency authorizations activated due to the current crisis, both Moderna’s and Inovio’s testing for these vaccines has skipped animal trials and gone straight to human testing. They are also set to be fast-tracked for widespread use in a matter of months. Moderna’s clinical trial in humans began in mid-March, followed by Inovio’s in the beginning of April. Thus, they are not only Gates’ favorites to be the new vaccine, but are also slated to be the first to complete clinical trials and garner emergency U.S. government approval, especially Moderna’s vaccine which is being jointly developed with the government’s NIH.

The rapid rise to prominence of Moderna’s and Inovio’s Covid-19 vaccines has resulted in several media articles praising DARPA as having provided our “best hope” for thwarting the coronavirus crisis. In addition to its backing of Moderna’s and Inovio’s own efforts, DARPA itself, specifically DARPA’s BTO, is set to have a “temporary” vaccine for Covid-19 available in a matter of weeks that will involve the production of synthetic antibodies that would ostensibly provide immunity for a few months until a longer-lasting vaccine (such as those produced by Moderna and Inovio) is available.

DARPA’s antibody treatment for Covid-19 is pursuing two routes, including the “human body as bio-reactor” approach that would involve synthetic DNA or RNA being injected in order to prompt the body to produce the necessary antibodies. Defense One notes that DARPA’s Covid-19 treatment would utilize techniques that had resulted from the agency’s investments in microfluidics (the manipulation of liquids at the sub-millimeter range), nanotechnology fabrication and “new approaches to gene sequencing.”

Persistent Concerns

While most media reports have painted these DARPA-led efforts as entirely positive, it is worth noting that concerns have been raised, though these concerns have hardly gotten the coverage they warrant. For instance, Nature recently noted some key points regarding safety issues related to the race for a Covid-19 vaccine, including the fact that all “previous coronavirus vaccines have not all proven appropriate or even safe,” with some past attempts at coronavirus vaccines having resulted in antibody dependent enhancement (ADE). ADE results in cells more rapidly taking up the virus and speeding up the virus’ replication, increasing its infectiousness and virulence.

Nature also noted that the two coronavirus vaccines for SARS that managed to pass phase 1 trials ended up, in subsequent studies, causing immune hypersensitivity in mice “resulting in severe immunopathology,” i.e. permanent defects or malfunctions in the immune system. In addition, Nature also pointed out that it is unknown how strong an immune response is needed to confer immunity for Covid-19 and coronaviruses in general, making it incredibly difficult to gauge if a vaccine is even effective.

Another issue worth noting involves concerns raised about Inovio Pharmaceuticals by investment research firm Citron Research, which compared Inovio to Theranos, the disgraced medical technology company that had initially promised to offer diagnoses for numerous diseases via a simple blood test, but was later revealed to be a sham. Citron asserted that “It’s been over 40 years since Inovio was founded, yet the company has NEVER [sic] brought a product to market, and all the while insiders have enriched themselves with hefty salaries and large stock sales.”

Citron Research went on to say that the company’s claim to have designed their Covid-19 vaccine in only 3 hours based on a computer algorithm was hard to believe, stating that “Inovio has a ‘computer algorithm’ that no one else in the world has and is arguably one of the greatest breakthroughs in vaccine discovery in the past 100 years, and yet this ‘computer algorithm’ is not mentioned once in any of its 10-K’s or 10-Q’s? Sounds like Theranos to us.” It also noted that Inovio’s partnerships with pharmaceutical companies Roche and AstraZeneca ended up failing with those two companies canceling the partnership despite claims from Inovio’s CEO that whey would “continue to thrive.”

A Not-So-Hidden Agenda

Of course, these are just concerns focused on corporate behavior and obstacles towards making a Covid-19 vaccine in general. As this report has already shown in detail, DARPA’s other experiments with the same technologies (particularly genetic engineering, synthetic chromosomes, and nanotechnology) that are being used to produce RNA and DNA vaccines for Covid-19 are arguably more concerning. This is especially true given that DARPA-backed companies that describe themselves as “strategic partners” of the agency are those manufacturing these vaccines. In addition, thanks to backing from the U.S. government and Bill Gate, among others, they are are also slated to be among the first vaccines (if not the first) approved for widespread use.

It is certainly troubling that media coverage of DARPA’s efforts and the efforts of Moderna and Inovio have thus far not included critical reporting regarding the different branches of DARPA’s research that has produced the technology involved in creating these vaccines, leaving little room for public scrutiny of their safety, efficacy and their potential for unintended effects on human genetics.

This is particularly alarming given that, over the past several weeks, efforts have been taking shape in many countries to enforce mandatory vaccinations once a Covid-19 vaccine becomes available. In some countries, it appears likely that the Covid-19 vaccine will not be made mandatory per say, but will be required for those who wish to return to any semblance of “normalcy” in terms of public gatherings, working certain jobs, leaving one’s home for longer periods of time and so on.

Would those involved in creating such a mandatory vaccine, e.g. DARPA, pass up the opportunity to utilize the same technologies involved in producing the vaccine for some of their other admitted goals? This question, of course, has no obvious answer, but the fact that the arc of DARPA’s research is aimed at the weaponization of human biology and genetics in a way that is ripe for misuse, suggests very worrying possibilities that warrant scrutiny. Indeed, if one merely looks at how the crisis has been a boon for the Orwellian plans of the National Security Commission on Artificial Intelligence (NSCAI) and the federal government’s current efforts to dramatically increase its powers amid the current crisis, it becomes increasingly difficult to give government agencies like DARPA and their corporate partners like Moderna and Inovio the benefit of the doubt.

This is especially true given that – without a major crisis such as that currently dominating world events – people would likely be unreceptive to the widespread introduction of many of the technologies DARPA has been developing, whether their push to create cyborg “super soldiers” or injectable BMIs with the capability to control one’s thoughts. Yet, amid the current crisis, many of these same technologies are being sold to the public as “healthcare,” a tactic DARPA often uses. As the panic and fear regarding the virus continues to build and as people become increasingly desperate to return to any semblance of normalcy, millions will willingly take a vaccine, regardless of any government-mandated vaccination program. Those who are fearful and desperate will not care that the vaccine may include nanotechnology or have the potential to genetically modify and re-program their very being, as they will only want the current crisis that has upended the world to stop.

In this context, the current coronavirus crisis appears to be the perfect storm that will allow DARPA’s dystopian vision to take hold and burst forth from the darkest recesses of the Pentagon into full public view. However, DARPA’s transhumanist vision for the military and for humanity presents an unprecedented threat, not just to human freedom, but an existential threat to human existence and the building blocks of biology itself.

Question Everything, Come To Your Own Conclusions.

May 4, 2020 Posted by | Civil Liberties, Deception, Militarism, Timeless or most popular | , , , , , , , | 1 Comment